Oxaliplatin Injection USP, in combination with infusional fluorouracil and leucovorin, is indicated for:

{ "type": "p", "children": [], "text": "Oxaliplatin Injection USP, in combination with infusional fluorouracil and leucovorin, is indicated for:" }

{ "type": "ul", "children": [ "  adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.", "  treatment of advanced colorectal cancer." ], "text": "" }

Administer oxaliplatin injection in combination with fluorouracil and leucovorin every 2 weeks.

Day 1

Administer oxaliplatin injection 85 mg/m 2as an intravenous infusion over 120 minutes and leucovorin 200 mg/m 2as an intravenous infusion over 120 minutes at the same time in separate bags, followed by fluorouracil 400 mg/m 2as intravenous bolus over 2-4 minutes, followed by fluorouracil 600 mg/m 2as a 22-hour continuous infusion.

Day 2

Administer leucovorin 200 mg/m 2as an intravenous infusion over 120 minutes, followed by fluorouracil 400 mg/m 2as intravenous bolus over 2-4 minutes, followed by fluorouracil 600 mg/m 2as a 22-hour continuous infusion.

Refer to the prescribing information for fluorouracil and leucovorin for additional information.

Prolongation of infusion time for oxaliplatin injection from 2 hours to 6 hours may mitigate acute toxicities, such as non-life-threatening infusion-related reactions.

Permanently discontinue oxaliplatin injection for any of the following:

Refer to the fluorouracil and leucovorin prescribing information for dosage modifications for adverse reactions.

Dosage Modifications for Adjuvant Treatment

Dosage modifications for adverse reactions for adjuvant treatment are presented in Table 1.

<div class="scrollingtable"><table width="100%"> <caption> <span>Table 1: Dosage Modifications for Adjuvant Treatment in Patients with Stage III Colon Cancer</span> </caption> <col width="33%"/> <col width="33%"/> <col width="33%"/> <tbody class="Headless"> <tr class="First"> <td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Adverse Reactions</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Severity</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection Dosage Modifications</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" rowspan="3" valign="top"> <p class="First">Peripheral Sensory Neuropathy <span class="Italics">[see Warnings and Precautions ( <a href="#_RefID40">5.2</a>)] </span> </p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Persistent Grade 2</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Consider reducing oxaliplatin injection dose to 75 mg/m <span class="Sup">2</span>. </p> </td> </tr> <tr> <td class="Botrule Rrule" valign="top"> <p class="First">Persistent Grade 3</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Consider discontinuing oxaliplatin injection.</p> </td> </tr> <tr> <td class="Botrule Rrule" valign="top"> <p class="First">Grade 4</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Discontinue oxaliplatin injection.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" rowspan="2" valign="top"> <p class="First">Myelosuppression <span class="Italics">[see Warnings and Precautions ( <a href="#_RefID46">5.3</a>), Adverse Reactions ( <a href="#_RefID65">6.1</a>)]. </span> </p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Grade 4 neutropenia or febrile neutropenia</p> </td><td class="Botrule Rrule" rowspan="2" valign="top"> <p class="First">Delay the next dose until neutrophils greater than or equal to 1.5 × 10 <span class="Sup">9</span>/L and platelets greater than or equal to 75 × 10 <span class="Sup">9</span>/L. Reduce oxaliplatin injection dose to 75 mg/m <span class="Sup">2</span> </p> </td> </tr> <tr> <td class="Botrule Rrule" valign="top"> <p class="First">Grade 3-4 thrombocytopenia</p> </td> </tr> <tr class="Last"> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Gastrointestinal Adverse Reactions <span class="Italics">[see Adverse Reactions ( <a href="#_RefID65">6.1</a>)] </span> </p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Grade 3-4</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">After recovery, reduce oxaliplatin injection dose to 75 mg/m <span class="Sup">2</span>along with a dose reduction of fluorouracil to 300 mg/m <span class="Sup">2</span>as an intravenous bolus and 500 mg/m <span class="Sup">2</span>as a 22-hour continuous infusion. </p> </td> </tr> </tbody> </table></div>

Dosage Modifications for Advanced Colorectal Cancer

Dosage modifications for adverse reactions for advanced colorectal cancer are presented in Table 2.

<div class="scrollingtable"><table width="100%"> <caption> <span>Table 2: Dosage Modifications for Advanced Colorectal Cancer</span> </caption> <col width="33%"/> <col width="33%"/> <col width="33%"/> <tbody class="Headless"> <tr class="First"> <td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Adverse Reactions</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Severity</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection Dosage Modifications</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" rowspan="3" valign="top"> <p class="First">Neuropathy <span class="Italics">[see Warnings and Precautions ( <a href="#_RefID40">5.2</a>)] </span> </p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Persistent Grade 2</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Consider reducing oxaliplatin injection dose to 65 mg/m <span class="Sup">2</span>. </p> </td> </tr> <tr> <td class="Botrule Rrule" valign="top"> <p class="First">Persistent Grade 3</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Consider discontinuing oxaliplatin injection.</p> </td> </tr> <tr> <td class="Botrule Rrule" valign="top"> <p class="First">Grade 4</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Discontinue oxaliplatin injection.</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" rowspan="2" valign="top"> <p class="First">Myelosuppression <span class="Italics">[see Warnings and Precautions ( <a href="#_RefID46">5.3</a>), Adverse Reactions ( <a href="#_RefID65">6.1</a>)] </span> </p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Grade 4 neutropenia or febrile neutropenia</p> </td><td class="Botrule Rrule" rowspan="2" valign="top"> <p class="First">Delay the next dose until neutrophils greater than or equal to 1.5 × 10 <span class="Sup">9</span>/L and platelets greater than or equal to 75 × 10 <span class="Sup">9</span>/L. <br/> Reduce oxaliplatin injection dose to 65 mg/m <span class="Sup">2</span>. </p> </td> </tr> <tr> <td class="Botrule Rrule" valign="top"> <p class="First">Grade 3-4 thrombocytopenia</p> </td> </tr> <tr class="Last"> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Gastrointestinal Adverse Reactions <span class="Italics">[see Adverse Reactions ( <a href="#_RefID65">6.1</a>)] </span> </p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Grade 3-4</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">After recovery, reduce oxaliplatin injection dose to 65 mg/m <span class="Sup">2</span>along with a dose reduction of fluorouracil to 300 mg/m <span class="Sup">2</span>as an intravenous bolus and 500 mg/m <span class="Sup">2</span>as a 22-hour continuous infusion <span class="Italics">.</span> </p> </td> </tr> </tbody> </table></div>

In patients with severe renal impairment (creatinine clearance [CLcr] less than 30 mL/min, calculated by the Cockcroft-Gault equation), reduce the oxaliplatin injection dose to 65 mg/m 2 [see Use in Specific Populations ( 8.6), Clinical Pharmacology ( 12.3)] .

Injection: 50 mg (5 mg/mL) or 100 mg (5 mg/mL) clear, colorless solution in a single-dose vial.

{ "type": "p", "children": [], "text": "Injection: 50 mg (5 mg/mL) or 100 mg (5 mg/mL) clear, colorless solution in a single-dose vial." }

Oxaliplatin Injection is contraindicated in patients with a history of a hypersensitivity reaction to oxaliplatin or other platinum-based drugs. Reactions have included anaphylaxis [see Warnings and Precautions ( 5.1)] .

{ "type": "p", "children": [], "text": "Oxaliplatin Injection is contraindicated in patients with a history of a hypersensitivity reaction to oxaliplatin or other platinum-based drugs. Reactions have included anaphylaxis\n \n [see Warnings and Precautions (\n \n 5.1)]\n \n .\n\n " }

Serious and fatal hypersensitivity reactions, including anaphylaxis, can occur with oxaliplatin injection within minutes of administration and during any cycle. Grade 3-4 hypersensitivity reactions, including anaphylaxis, occurred in 2% to 3% of patients with colon cancer who received oxaliplatin injection. Hypersensitivity reactions, including rash, urticaria, erythema, pruritus, and rarely, bronchospasm and hypotension, were similar in nature and severity to those reported with other platinum-based drugs.

Oxaliplatin Injection is contraindicated in patients with hypersensitivity reactions to platinum-based drugs [see Contraindications ( 4)] . Immediately and permanently discontinue oxaliplatin injection for hypersensitivity reactions and administer appropriate treatment for management of hypersensitivity reactions.

Oxaliplatin Injection can cause acute and delayed neuropathy. Reduce the dose or permanently discontinue oxaliplatin injection for persistent neurosensory reactions based on the severity of the adverse reaction [see Dosage and Administration (2.2)].

Acute Neuropathy

Acute neuropathy typically presents as a reversible, primarily peripheral sensory neuropathy that occurs within hours or 2 days following a dose, resolves within 14 days, and frequently recurs with further dosing. The symptoms can be precipitated or exacerbated by exposure to cold temperature or cold objects and they usually present as transient paresthesia, dysesthesia and hypoesthesia in the hands, feet, perioral area, or throat. Jaw spasm, abnormal tongue sensation, dysarthria, eye pain, and a feeling of chest pressure have also been observed. The acute, reversible pattern of sensory neuropathy was observed in about 56% of patients who received oxaliplatin injection with fluorouracil/leucovorin. In any individual cycle, acute neuropathy occurred in approximately 30% of patients. For grade 3 peripheral sensory neuropathy, the median time to onset was 9 cycles for adjuvant treatment and 6 cycles for previously treated advanced colorectal cancer.

An acute syndrome of pharyngolaryngeal dysesthesia occurred in 1% to 2% (grade 3-4) of patients previously untreated for advanced colorectal cancer. Subjective sensations of dysphagia or dyspnea, without any laryngospasm or bronchospasm (no stridor or wheezing) occurred in patients previously treated for advanced colorectal cancer.

Avoid topical application of ice for mucositis prophylaxis or other conditions, because cold temperature can exacerbate acute neurological symptoms .

Delayed Neuropathy

Delayed neuropathy typically presents as a persistent (greater than 14 days), primarily peripheral sensory neuropathy that is usually characterized by paresthesias, dysesthesias, and hypoesthesias, but may also include deficits in proprioception that can interfere with daily activities (e.g., writing, buttoning, swallowing, and difficulty walking from impaired proprioception). These forms of neuropathy occurred in 48% of patients receiving oxaliplatin injection. Delayed neuropathy can occur without any prior acute neuropathy. Most patients (80%) who developed grade 3 persistent neuropathy progressed from prior grade 1 or 2 reactions. These symptoms may improve in some patients upon discontinuation of oxaliplatin injection.

Adjuvant treatment

In the adjuvant treatment trial, neuropathy was graded using NCI CTC, version 1 as summarized in Table 3.

<div class="scrollingtable"><table width="100%"> <caption> <span>Table 3: Grading for Neuropathy in Adjuvant Treatment Trial</span> </caption> <col width="21%"/> <col width="79%"/> <tbody class="Headless"> <tr class="First"> <td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Grade</span> </p> </td><td class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Definition</span> </p> </td> </tr> <tr> <td align="center" class="Botrule Lrule Rrule" valign="top"> <p class="First">0</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">No change or none</p> </td> </tr> <tr> <td align="center" class="Botrule Lrule Rrule" valign="top"> <p class="First">1</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Mild paresthesias, loss of deep tendon reflexes</p> </td> </tr> <tr> <td align="center" class="Botrule Lrule Rrule" valign="top"> <p class="First">2</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Mild or moderate objective sensory loss, moderate paresthesias</p> </td> </tr> <tr> <td align="center" class="Botrule Lrule Rrule" valign="top"> <p class="First">3</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Severe objective sensory loss or paresthesias that interfere with function</p> </td> </tr> <tr class="Last"> <td align="center" class="Botrule Lrule Rrule" valign="top"> <p class="First">4</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Not applicable</p> </td> </tr> </tbody> </table></div>

Peripheral sensory neuropathy occurred in 92% of patients (all grades), including 13% of patients (grade 3) who received oxaliplatin injection with fluorouracil/leucovorin. At the 28-day follow-up after the last treatment cycle, 60% of patients had any grade (grade 1=40%, grade 2=16%, grade 3=5%) peripheral sensory neuropathy, decreasing to 39% at 6 months of follow-up (grade 1=31%, grade 2=7%, grade 3=1%) and 21% at 18 months of follow-up (grade 1=17%, grade 2=3%, grade 3=1%).

Advanced colorectal cancer

In the advanced colorectal cancer trials, neuropathy was graded using the neurotoxicity scale summarized in Table 4.

<div class="scrollingtable"><table width="100%"> <caption> <span>Table 4: Grading for Neuropathy in Advanced Colorectal Cancer Trials</span> </caption> <col width="20%"/> <col width="80%"/> <tbody class="Headless"> <tr class="First"> <td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Grade</span> </p> </td><td class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Definition</span> </p> </td> </tr> <tr> <td align="center" class="Botrule Lrule Rrule" valign="top"> <p class="First">1</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Resolved and did not interfere with functioning</p> </td> </tr> <tr> <td align="center" class="Botrule Lrule Rrule" valign="top"> <p class="First">2</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Interfered with function but not daily activities</p> </td> </tr> <tr> <td align="center" class="Botrule Lrule Rrule" valign="top"> <p class="First">3</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Pain or functional impairment that interfered with daily activities</p> </td> </tr> <tr class="Last"> <td align="center" class="Botrule Lrule Rrule" valign="top"> <p class="First">4</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Persistent impairment that is disabling or life-threatening</p> </td> </tr> </tbody> </table></div>

Neuropathy occurred in 82% (all grades) of patients previously untreated for advanced colorectal cancer, including 19% grade 3-4; and in 74% (all grades) of patients previously treated for advanced colorectal cancer, including 7% grade 3-4.

Grade 3 or 4 neutropenia occurred in 41% to 44% of patients with colorectal cancer who received oxaliplatin injection with fluorouracil/leucovorin. Sepsis, neutropenic sepsis and septic shock, including fatal outcomes, occurred in patients who received oxaliplatin injection [see Adverse Reactions ( 6.1, 6.2)] .

Grade 3 or 4 thrombocytopenia occurred in 2% to 5% of patients with colorectal cancer who received oxaliplatin injection with fluorouracil/leucovorin.

Monitor complete blood cell count at baseline, before each subsequent cycle and as clinically indicated .Delay oxaliplatin injection until neutrophils are greater than or equal to 1.5 x 10 9/L and platelets are greater than or equal to 75 × 10 9/L. Withhold oxaliplatin injection for sepsis or septic shock. Dose reduce oxaliplatin injection after recovery from grade 4 neutropenia, febrile neutropenia or grade 3-4 thrombocytopenia as recommended [see Dosage and Administration ( 2.2)] .

PRES occurred in less than 0.1% of patients across clinical trials [see Adverse Reactions ( 6.1)] . Signs and symptoms of PRES can include headache, altered mental functioning, seizures, abnormal vision from blurriness to blindness, associated or not with hypertension. Confirm the diagnosis of PRES with magnetic resonance imaging. Permanently discontinue oxaliplatin injection in patients who develop PRES.

Oxaliplatin Injection has been associated with pulmonary fibrosis (less than 1% of patients), which may be fatal [see Adverse Reactions ( 6.1)].

In the adjuvant treatment trial, the combined incidence of cough and dyspnea was 7.4% (any grade), including less than 1% (grade 3) in the oxaliplatin injection arm. One patient died from eosinophilic pneumonia in the oxaliplatin injection arm.

In the previously untreated advanced colorectal cancer trial, the combined incidence of cough, dyspnea, and hypoxia was 43% (any grade), including 7% (grade 3-4) in the oxaliplatin injection with fluorouracil/leucovorin arm.

In case of unexplained respiratory symptoms, such as non-productive cough, dyspnea, crackles, or radiological pulmonary infiltrates, withhold oxaliplatin injection until further pulmonary investigation excludes interstitial lung disease or pulmonary fibrosis. Permanently discontinue oxaliplatin injection for confirmed interstitial lung disease or pulmonary fibrosis.

In the adjuvant treatment trial, increased transaminases (57% vs 34%) and alkaline phosphatase (42% vs 20%) occurred more commonly in the oxaliplatin injection arm than in the fluorouracil/leucovorin arm [see Adverse Reactions ( 6.1)] . The incidence of increased bilirubin was similar on both arms. Changes noted on liver biopsies include: peliosis, nodular regenerative hyperplasia or sinusoidal alterations, perisinusoidal fibrosis, and veno-occlusive lesions.

Consider evaluating patients who develop abnormal liver tests or portal hypertension which cannot be explained by liver metastases, for hepatic vascular disorders. Monitor liver function tests at baseline, before each subsequent cycle, and as clinically indicated.

QT prolongation and ventricular arrhythmias, including fatal torsade de pointes, have been reported with oxaliplatin injection [see Adverse Reactions ( 6.2)] .

Avoid oxaliplatin injection in patients with congenital long QT syndrome. Monitor electrocardiograms (ECG) in patients with congestive heart failure, bradyarrhythmias, and electrolyte abnormalities and in patients taking drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics [see Drug Interactions ( 7.1)] . Monitor and correct electrolyte abnormalities prior to initiating oxaliplatin injection and periodically during treatment.

Rhabdomyolysis, including fatal cases, has been reported with oxaliplatin injection [see Adverse Reactions ( 6.2)] . Permanently discontinue oxaliplatin injection for any signs or symptoms of rhabdomyolysis .

The incidence of hemorrhage in clinical trials was higher on the oxaliplatin injection combination arm compared to the fluorouracil/leucovorin arm. These reactions included gastrointestinal bleeding, hematuria, and epistaxis. In the adjuvant treatment trial, 2 patients died from intracerebral hemorrhage [see Adverse Reactions ( 6.1)] .

Prolonged prothrombin time and INR occasionally associated with hemorrhage have been reported in patients who received oxaliplatin injection with fluorouracil/leucovorin while on anticoagulants [see Adverse Reactions ( 6.2)] . Increase frequency of monitoring in patients who are receiving oxaliplatin injection with fluorouracil/leucovorin and oral anticoagulants [see Drug Interactions ( 7.3)] .

Thrombocytopenia and immune-mediated thrombocytopenia have been observed with oxaliplatin injection. Rapid onset of thrombocytopenia and greater risk of bleeding have been observed in immune-mediated thrombocytopenia. In this case, consider discontinuing oxaliplatin injection.

Based on findings from animal studies and its mechanism of action, oxaliplatin injection can cause fetal harm when administered to a pregnant woman. The available human data do not establish the presence or absence of major birth defects or miscarriage related to the use of oxaliplatin injection. Reproductive toxicity studies demonstrated adverse effects on embryo-fetal development in rats at maternal doses that were below the recommended human dose based on body surface area. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with oxaliplatin injection and for 9 months after the final dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with oxaliplatin injection and for 6 months after the final dose [see Use in Specific Populations ( 8.1, 8.3)].

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

More than 1100 patients with stage II or III colon cancer and more than 4,000 patients with advanced colorectal cancer were treated in trials with oxaliplatin injection. The most common adverse reactions in patients with stage II or III colon cancer receiving adjuvant treatment were peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, emesis, fatigue and stomatitis. The most common adverse reactions in previously untreated and treated patients with advanced colorectal cancer were peripheral sensory neuropathies, fatigue, neutropenia, nausea, emesis, and diarrhea.

Adjuvant Treatment

The safety of oxaliplatin injection in combination with fluorouracil (FU)/leucovorin (LV) was evaluated in patients with stage II or III colon cancer, who had undergone complete resection of the primary tumor in the adjuvant treatment trial [see Clinical Studies ( 14.1)].

Fatal adverse reactions in patients who received oxaliplatin injection in the combination arm included sepsis/neutropenic sepsis (n=3), intracerebral hemorrhage (n=2), and eosinophilic pneumonia (n=1).

Thromboembolic events occurred in 6% (grade 3-4, 1.2%) of patients in the oxaliplatin injection arm.

Grade 3 or 4 adverse reactions occurred in 70% of patients in the oxaliplatin injection arm. Grade 3-4 gastrointestinal bleeding occurred in 0.2% of patients. Febrile neutropenia occurred in 0.7% and documented infection with concomitant grade 3-4 neutropenia occurred in 1.1%.

Discontinuation due to an adverse reaction occurred in 15% of the patients in the oxaliplatin injection arm.

Tables 5, 6, and 7 summarize the adverse reactions reported in patients with colon cancer receiving adjuvant treatment.

<div class="scrollingtable"><table width="80%"> <caption> <span>Table 5: Adverse Reactions Reported in Patients with Colon Cancer Receiving Adjuvant Treatment (greater than or equal to 5% of all patients and with greater than or equal to 1% grade 3–4)</span> </caption> <col width="27%"/> <col width="17%"/> <col width="16%"/> <col width="16%"/> <col width="17%"/> <thead> <tr class="First"> <th align="left" class="Lrule Rrule Toprule" valign="top"></th><th align="center" class="Botrule Rrule Toprule" colspan="2" valign="top"><span class="Bold">Oxaliplatin Injection + FU/LV</span> <br/> <span class="Bold">N=1108</span></th><th align="center" class="Botrule Rrule Toprule" colspan="2" valign="top"><span class="Bold">FU/LV</span> <br/> <span class="Bold">N=1111</span></th> </tr> <tr class="Last"> <th align="left" class="Botrule Lrule Rrule" valign="top"><span class="Bold">Adverse Reaction</span></th><th align="center" class="Botrule Rrule" valign="top"><span class="Bold">All Grades</span> <br/> <span class="Bold">(%)</span></th><th align="center" class="Botrule Rrule" valign="top"><span class="Bold">Grade 3–4</span> <br/> <span class="Bold">(%)</span></th><th align="center" class="Botrule Rrule" valign="top"><span class="Bold">All Grades</span> <br/> <span class="Bold">(%)</span></th><th align="center" class="Botrule Rrule" valign="top"><span class="Bold">Grade 3–4</span> <br/> <span class="Bold">(%)</span></th> </tr> </thead> <tbody> <tr class="First"> <td class="Lrule Rrule Toprule" colspan="5" valign="middle"> <p class="First"> <span class="Bold">Neurology</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">Peripheral Sensory Neuropathy</p> </td><td align="center" class="Botrule Rrule Toprule" valign="middle"> <p class="First">92</p> </td><td align="center" class="Botrule Rrule Toprule" valign="middle"> <p class="First">12</p> </td><td align="center" class="Botrule Rrule Toprule" valign="middle"> <p class="First">16</p> </td><td align="center" class="Botrule Rrule Toprule" valign="middle"> <p class="First">&lt;1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="5" valign="middle"> <p class="First"> <span class="Bold">Gastrointestinal</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Nausea</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">74</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">61</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Diarrhea</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">56</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">48</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Vomiting</p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First">47</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">24</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Stomatitis</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">42</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">40</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Anorexia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">13</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">&lt;1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="5" valign="middle"> <p class="First"> <span class="Bold">Constitutional Symptoms/Pain</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Fatigue</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">44</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">38</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Abdominal Pain</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">18</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">17</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="5" valign="middle"> <p class="First"> <span class="Bold">Dermatology/Skin</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Skin Disorder</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">32</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">36</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Injection Site Reaction †</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="5" valign="middle"> <p class="First"> <span class="Bold">Fever/Infection</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Fever</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">27</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">12</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Infection</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">25</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">25</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="5" valign="middle"> <p class="First"> <span class="Bold">Allergy/Immunology</span> </p> </td> </tr> <tr class="Last"> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Allergic Reaction</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">&lt;1</p> </td> </tr> </tbody> </table></div>

* Event coded in WHO-ART dictionary

† Includes thrombosis related to the catheter

<div class="scrollingtable"><table width="80%"> <caption> <span>Table 6: Adverse Reactions Reported in Patients with Colon Cancer Receiving Adjuvant Treatment (greater than or equal to 5% of all patients but with less than 1% grade 3-4)</span> </caption> <col width="31%"/> <col width="31%"/> <col width="31%"/> <tbody class="Headless"> <tr class="First"> <td align="center" class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"> <p class="First"> <span class="Bold">Adverse Reaction</span>* </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection + FU/LV N=1108</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">FU/LV N=1111</span> </p> </td> </tr> <tr> <td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All Grades (%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All Grades (%)</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Dermatology/Skin</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Alopecia†</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">30</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">28</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First"> <span class="Bold">Gastrointestinal</span> </p> </td><td class="Botrule Rrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Constipation</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">22</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">19</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Taste Perversion</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">12</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Dyspepsia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Constitutional Symptoms/Pain/Ocular/Visual</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Epistaxis</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">16</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">12</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Weight Increase</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Conjunctivitis</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">15</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Headache</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Dyspnea</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Pain</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Abnormal Lacrimation</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">12</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Neurology</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Sensory Disturbance</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Allergy/Immunology</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Rhinitis</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8</p> </td> </tr> <tr class="Last"> <td class="Botrule" colspan="3" valign="top"> <p class="First">* Event coded in WHO-ART dictionary <br/> † No complete alopecia was reported </p> </td> </tr> </tbody> </table></div>

In females, the following grade 3-4 adverse reactions were more frequent: diarrhea, fatigue, neutropenia, nausea, and vomiting.

In patients greater than or equal to 65 years old, the incidence of grade 3-4 diarrhea and neutropenia was higher than in younger adults.

Clinically relevant adverse reactions were reported in greater than or equal to 2% and less than 5% of the patients in the oxaliplatin injection arm (listed in decreasing order of frequency) were pain, leukopenia, weight loss, and cough.

<div class="scrollingtable"><table width="100%"> <caption> <span>Table 7: Laboratory-Related Adverse Reactions Occurring in ≥5% of Patients with Colon Cancer Receiving Adjuvant Treatment</span> </caption> <col width="21%"/> <col width="21%"/> <col width="21%"/> <col width="21%"/> <col width="18%"/> <tbody class="Headless"> <tr class="First"> <td align="center" class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"> <p class="First"> <span class="Bold">Laboratory-Related Adverse Reaction</span> </p> </td><td align="center" class="Botrule Rrule Toprule" colspan="2" valign="top"> <p class="First"> <br/> <span class="Bold">Oxaliplatin Injection with FU/LV N=1108</span> </p> </td><td align="center" class="Botrule Rrule Toprule" colspan="2" valign="top"> <p class="First"> <br/> <span class="Bold">FU/LV N=1111</span> </p> </td> </tr> <tr> <td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All Grades (%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">Grades 3-4 (%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All Grades (%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">Grades 3-4 (%)</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="5" valign="top"> <p class="First"> <span class="Bold">Hematology</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Neutropenia</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">79</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">41</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">40</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">5</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Thrombocytopenia</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">77</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">19</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">&lt;1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Anemia</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">76</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">67</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">&lt;1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="5" valign="top"> <p class="First"> <span class="Bold">Hepatic</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Increased Transaminases</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">57</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">34</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Increased Alkaline Phosphatase</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">42</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">&lt;1</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">20</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">&lt;1</p> </td> </tr> <tr class="Last"> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Hyperbilirubinemia</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">20</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">20</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">5</p> </td> </tr> </tbody> </table></div>

Previously Untreated Advanced Colorectal Cancer

The safety of oxaliplatin injection in combination with fluorouracil (FU)/leucovorin (LV) was evaluated in a randomized trial of patients with previously untreated advanced colorectal cancer [see Clinical Studies ( 14.2)]. The adverse reaction profile in this trial was similar to that seen in other trials.

Tables 8, 9, and 10 summarize the adverse reactions reported in the previously untreated advanced colorectal cancer trial.

<div class="scrollingtable"><table width="100%"> <caption> <span>Table 8: Adverse Reactions Reported in Patients in the Previously Untreated Advanced Colorectal Cancer Clinical Trial (greater than or equal to 5% of all patients and with greater than or equal to 1% grade 3-4)</span> </caption> <col width="22%"/> <col width="18%"/> <col width="16%"/> <col width="16%"/> <col width="11%"/> <col width="8%"/> <col width="9%"/> <tbody class="Headless"> <tr class="First"> <td align="center" class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"> <p class="First"> <span class="Bold">Adverse Reaction*</span> </p> </td><td align="center" class="Botrule Rrule Toprule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection +</span> <br/> <span class="Bold">FU/LV</span> <br/> <span class="Bold">N=259</span> </p> </td><td align="center" class="Botrule Rrule Toprule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Irinotecan +</span> <br/> <span class="Bold">FU/LV</span> <br/> <span class="Bold">N=256</span> </p> </td><td align="center" class="Botrule Rrule Toprule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection +</span> <br/> <span class="Bold">Irinotecan</span> <br/> <span class="Bold">N=258</span> </p> </td> </tr> <tr> <td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All</span> <br/> <span class="Bold">Grades</span> <br/> <span class="Bold">(%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">Grades</span> <br/> <span class="Bold">3-4</span> <br/> <span class="Bold">(%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All</span> <br/> <span class="Bold">Grades</span> <br/> <span class="Bold">(%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">Grades</span> <br/> <span class="Bold">3-4</span> <br/> <span class="Bold">(%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All</span> <br/> <span class="Bold">Grades</span> <br/> <span class="Bold">(%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">Grades</span> <br/> <span class="Bold">3-4</span> <br/> <span class="Bold">(%)</span> </p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Neurology</span> </p> </td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule Rrule" colspan="2" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Neuropathy</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">82</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">19</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">18</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">69</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Paresthesias</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">77</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">18</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">16</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">62</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Pharyngo-laryngeal Dysesthesias</p> </td><td align="center" class="Botrule Rrule" valign="bottom"> <p class="First">38</p> </td><td align="center" class="Botrule Rrule" valign="bottom"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="bottom"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="bottom"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="bottom"> <p class="First">28</p> </td><td align="center" class="Botrule Rrule" valign="bottom"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Neuro-sensory</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">12</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Neuro NOS <span class="Sup">†</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> 0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> 1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> 1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> 0</p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Gastrointestinal</span> </p> </td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule Rrule" colspan="2" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Nausea</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">71</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">67</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">15</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">83</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">19</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Diarrhea</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">56</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">12</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">65</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">29</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">76</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">25</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Vomiting</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">41</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">43</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">13</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">64</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">23</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Stomatitis</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">38</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">25</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">19</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Anorexia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">35</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">25</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">27</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Constipation</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">32</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">27</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">21</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Diarrhea-colostomy</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">13</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">16</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">16</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Gastrointestinal NOS <span class="Sup">†</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> 2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> 4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> 3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Constitutional Symptoms/Pain/Ocular/Visual</span> </p> </td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule Rrule" colspan="2" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Fatigue</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">70</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">58</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">66</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">16</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Abdominal Pain</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">29</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">31</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">39</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Myalgia                 </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">14</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> 2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Pain                 </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Abnormal Vision</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Neuralgia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Pulmonary</span> </p> </td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule Rrule" colspan="2" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Cough</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">35</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">25</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">17</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Dyspnea</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">18</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">14</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Hiccups                 </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Hepatic/Metabolic/Laboratory/Renal</span> </p> </td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule Rrule" colspan="2" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Hyperglycemia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">14</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">12</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Hypokalemia                 </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> 3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Dehydration</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">16</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">14</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Hypoalbuminemia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Hyponatremia                 </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Urinary Frequency</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule" valign="top"> <p class="First"> <span class="Bold">Hematology/Infection</span> </p> </td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule Rrule" colspan="2" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Infection Normal ANC <span class="Sup">‡</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> 4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> 1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Infection Low ANC <span class="Sup">‡</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">12</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> 9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Lymphopenia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Febrile Neutropenia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">15</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">14</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">12</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td> </tr> <tr> <td class="Botrule Lrule" valign="top"> <p class="First"> <span class="Bold">Dermatology/Skin</span> </p> </td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule Rrule" colspan="2" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Hand/Foot Syndrome</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Injection Site Reaction</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule" valign="top"> <p class="First"> <span class="Bold">Cardiovascular</span> </p> </td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule Rrule" colspan="2" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Thrombosis                 </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Hypotension</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td> </tr> <tr class="Last"> <td class="Botrule" colspan="7" valign="top"> <p class="First">* Event coded in WHO-ART dictionary <br/> † Not otherwise specified <br/> ‡ Absolute neutrophil count </p> </td> </tr> </tbody> </table></div>

<div class="scrollingtable"><table width="100%"> <caption> <span>Table 9: Adverse Reactions Reported in Patients in the Previously Untreated Advanced Colorectal Cancer Clinical Trial (greater than or equal to 5% of all patients but with less than 1% grade 3-4)</span> </caption> <col width="25%"/> <col width="25%"/> <col width="25%"/> <col width="25%"/> <tbody class="Headless"> <tr class="First"> <td align="center" class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"> <p class="First"> <span class="Bold">Adverse Reaction*</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection +</span> <br/> <span class="Bold">FU/LV</span> <br/> <span class="Bold">N=259</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Irinotecan +</span> </p> <p> <span class="Bold">FU/LV</span> <br/> <span class="Bold">N=256</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection +</span> <br/> <span class="Bold">Irinotecan</span> <br/> <span class="Bold">N=258</span> </p> </td> </tr> <tr> <td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All Grades (%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All Grades (%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All Grades (%)</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First"> <span class="Bold">Dermatology/Skin</span> </p> </td><td class="Botrule Rrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Alopecia <span class="Sup">†</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">38</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">44</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">67</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Flushing</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Pruritus</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Dry Skin</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First"> <span class="Bold">Hematology/Infection</span> </p> </td><td class="Botrule Rrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Fever Normal ANC <span class="Sup">‡</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">16</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First"> <span class="Bold">Cardiovascular</span> </p> </td><td class="Botrule Rrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Edema</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">15</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">13</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First"> <span class="Bold">Gastrointestinal</span> </p> </td><td class="Botrule Rrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Taste Perversion</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">14</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Dyspepsia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">12</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Flatulence</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Mouth Dryness</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Constitutional Symptoms/Pain/Ocular/Visual</span> </p> </td><td class="Botrule Rrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Headache</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">13</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Weight Loss</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Epistaxis</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Tearing</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Rigors</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Dysphasia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Sweating</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">12</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Arthralgia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Neurology</span> </p> </td><td class="Botrule Rrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Insomnia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">13</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Depression</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Dizziness</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Anxiety</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Allergy/Immunology</span> </p> </td><td class="Botrule Rrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Rash</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Rhinitis Allergic</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Hepatic/Metabolic/Laboratory/Renal</span> </p> </td><td class="Botrule Rrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Hypocalcemia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Elevated Creatinine</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td> </tr> <tr class="Last"> <td class="Botrule" colspan="4" valign="top"> <p class="First">* Event coded in WHO-ART dictionary <br/> <span class="Sup">†</span>No complete alopecia was reported. <br/> <span class="Sup">‡</span>Absolute neutrophil count </p> </td> </tr> </tbody> </table></div>

Clinically relevant adverse reactions that occurred in greater than or equal to 2% and less than 5% of the patients in the oxaliplatin injection and fluorouracil/leucovorin combination arm (listed in decreasing order of frequency) were: metabolic, pneumonitis, catheter infection, vertigo, prothrombin time, pulmonary, rectal bleeding, dysuria, nail changes, chest pain, rectal pain, syncope, hypertension, hypoxia, unknown infection, bone pain, pigmentation changes, and urticaria.

<div class="scrollingtable"><table width="100%"> <caption> <span>Table 10: Laboratory-Related Adverse Reactions Occurring in ≥5% of Patients in the Previously Untreated Advanced Colorectal Cancer Trial </span> </caption> <col width="18%"/> <col width="17%"/> <col width="17%"/> <col width="17%"/> <col width="13%"/> <col width="8%"/> <col width="8%"/> <tbody class="Headless"> <tr class="First"> <td align="center" class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"> <p class="First"> <span class="Bold">Laboratory-Related Adverse Reaction</span> </p> </td><td align="center" class="Botrule Rrule Toprule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection and FU/LV</span> <br/> <span class="Bold">N=259</span> </p> </td><td align="center" class="Botrule Rrule Toprule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Irinotecan and FU/LV</span> <br/> <span class="Bold">N=256</span> </p> </td><td align="center" class="Botrule Rrule Toprule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection and Irinotecan</span> <br/> <span class="Bold">N=258</span> </p> </td> </tr> <tr> <td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All</span> <br/> <span class="Bold">Grades</span> <br/> <span class="Bold">(%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">Grades</span> <br/> <span class="Bold">3-4</span> <br/> <span class="Bold">(%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All</span> <br/> <span class="Bold">Grades</span> <br/> <span class="Bold">(%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">Grades</span> <br/> <span class="Bold">3-4</span> <br/> <span class="Bold">(%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All</span> <br/> <span class="Bold">Grades</span> <br/> <span class="Bold">(%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">Grades</span> <br/> <span class="Bold">3-4</span> <br/> <span class="Bold">(%)</span> </p> </td> </tr> <tr> <td class="Botrule Lrule" valign="top"> <p class="First"> <span class="Bold">Hematology</span> </p> </td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule Rrule" colspan="2" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Leukopenia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">85</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">20</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">84</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">23</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">76</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">24</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Neutropenia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">81</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">53</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">77</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">44</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">71</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">36</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Thrombocytopenia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">71</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">26</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">44</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Anemia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">27</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">28</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">25</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td> </tr> <tr> <td class="Botrule Lrule" valign="top"> <p class="First"> <span class="Bold">Hepatic</span> </p> </td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule Rrule" colspan="2" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Increased AST *</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">17</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Increased Alkaline Phosphatase</p> </td><td align="center" class="Botrule Rrule" valign="bottom"> <p class="First">16</p> </td><td align="center" class="Botrule Rrule" valign="bottom"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="bottom"> <p class="First">8</p> </td><td align="center" class="Botrule Rrule" valign="bottom"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="bottom"> <p class="First">14</p> </td><td align="center" class="Botrule Rrule" valign="bottom"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Hyperbilirubinemia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Increased ALT <span class="Sup">†</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr class="Last"> <td class="Botrule" colspan="7" valign="top"> <p class="First">* Aspartate transaminase <br/> <span class="Sup">†</span>Alanine transaminase </p> </td> </tr> </tbody> </table></div>

Previously Treated Advanced Colorectal Cancer

The safety of oxaliplatin injection in combination with fluorouracil (FU)/leucovorin (LV) was evaluated in a randomized trial in patients with refractory and relapsed colorectal cancer [see Clinical Studies ( 14.3)] . The adverse reaction profile in this trial was similar to that seen in other trials.

Three patients who received oxaliplatin injection in the combination arm experienced fatal adverse reactions: gastrointestinal bleeding and dehydration.

Grade 3 and 4 neutropenia were reported in 27% and 17% of patients, respectively, in the oxaliplatin injection with fluorouracil/leucovorin combination arm. Grade 3-4 increased serum creatinine occurred in 1% of patients in the oxaliplatin injection with combination fluorouracil/leucovorin arm.

Thirteen percent of patients in the oxaliplatin injection with fluorouracil/leucovorin combination arm discontinued treatment; the most frequent reasons were gastrointestinal adverse reactions, hematologic adverse reactions and neuropathies.

Tables 11, 12, and 13 summarize the adverse reactions reported in the previously treated advanced colorectal cancer trial.

<div class="scrollingtable"><table width="100%"> <caption> <span>Table 11: Adverse Reactions Reported in Patients in the Previously Treated Advanced Colorectal Cancer Trial (greater than or equal to 5% of all patients and with greater than or equal to 1% grade 3-4)</span> </caption> <col width="18%"/> <col width="17%"/> <col width="17%"/> <col width="17%"/> <col width="14%"/> <col width="8%"/> <col width="9%"/> <tbody class="Headless"> <tr class="First"> <td align="center" class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"> <p class="First"> <span class="Bold">Adverse Reaction*</span> </p> </td><td align="center" class="Botrule Rrule Toprule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection + FU/LV</span> <br/> <span class="Bold">N=150</span> </p> </td><td align="center" class="Botrule Rrule Toprule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection N=153</span> </p> </td><td align="center" class="Botrule Rrule Toprule" colspan="2" valign="top"> <p class="First"> <span class="Bold">FU/LV</span> <br/> <span class="Bold">N=142</span> </p> </td> </tr> <tr> <td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All</span> <br/> <span class="Bold">Grades</span> <br/> <span class="Bold">(%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">Grades</span> <br/> <span class="Bold">3-4</span> <br/> <span class="Bold">(%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All</span> <br/> <span class="Bold">Grades</span> <br/> <span class="Bold">(%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">Grades</span> <br/> <span class="Bold">3-4</span> <br/> <span class="Bold">(%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All</span> <br/> <span class="Bold">Grades</span> <br/> <span class="Bold">(%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">Grades</span> <br/> <span class="Bold">3-4</span> <br/> <span class="Bold">(%)</span> </p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Neurology</span> </p> </td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule Rrule" colspan="2" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Neuropathy</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">74</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">76</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">17</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">     Acute </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">56</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">65</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">     Persistent  </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">48</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">43</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Constitutional Symptoms/Pain</span> </p> </td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule Rrule" colspan="2" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Fatigue</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">68</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">61</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">52</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Back Pain</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">19</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">16</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Pain</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">15</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">14</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Gastrointestinal                        </span> </p> </td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule Rrule" colspan="2" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Diarrhea</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">67</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">46</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">44</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Nausea</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">65</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">64</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">59</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Vomiting</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">40</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">37</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">27</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Stomatitis</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">37</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">14</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">32</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Abdominal Pain</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">33</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">31</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">31</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Anorexia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">29</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">20</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">20</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Gastroesophageal Reflux</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Hematology/Infection</span> </p> </td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule Rrule" colspan="2" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Fever</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">29</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">25</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">23</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Febrile Neutropenia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Cardiovascular</span> </p> </td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule Rrule" colspan="2" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Dyspnea</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">20</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">13</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Coughing</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">19</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Edema</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">15</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">13</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Thromboembolism</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Chest Pain</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Dermatology/Skin</span> </p> </td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule Rrule" colspan="2" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Injection Site Reaction</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Hepatic/Metabolic/Laboratory/Renal</span> </p> </td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule Rrule" colspan="2" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Hypokalemia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Dehydration</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td> </tr> <tr class="Last"> <td class="Botrule" colspan="7" valign="top"> <p class="First">*Event coded in WHO-ART dictionary</p> </td> </tr> </tbody> </table></div>

<div class="scrollingtable"><table width="100%"> <caption> <span>Table 12: Adverse Reactions Reported in Patients in the Previously Treated Advanced Colorectal Cancer Clinical Trial (greater than or equal to 5% of all patients but with less than 1% grade 3-4)</span> </caption> <col width="25%"/> <col width="25%"/> <col width="25%"/> <col width="25%"/> <tbody class="Headless"> <tr class="First"> <td align="center" class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"> <p class="First"> <span class="Bold">Adverse Reaction*</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection + FU/LV</span> <br/> <span class="Bold">N=150</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection</span> <br/> <span class="Bold">N=153</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">FU/LV</span> <br/> <span class="Bold">N=142</span> </p> </td> </tr> <tr> <td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All Grades (%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All Grades (%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All Grades (%)</span> </p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Gastrointestinal</span> </p> </td><td class="Botrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Constipation</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">32</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">31</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">23</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Dyspepsia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">14</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Taste Perversion</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">13</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Mucositis</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Flatulence</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Constitutional Symptoms/Pain/Ocular/Visual</span> </p> </td><td class="Botrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Headache</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">17</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">13</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Arthralgia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Epistaxis</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Abnormal Lacrimation </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Rigors</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Allergy/Immunology</span> </p> </td><td class="Botrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Rhinitis</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">15</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Allergic Reaction</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Rash</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Neurology</span> </p> </td><td class="Botrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Dizziness</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">13</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Insomnia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Dermatology/Skin</span> </p> </td><td class="Botrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Hand-Foot Syndrome</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">13</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Flushing</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Alopecia <span class="Sup">†</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> 7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Pulmonary</span> </p> </td><td class="Botrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Upper Respiratory Tract Infection</p> </td><td align="center" class="Botrule Rrule" valign="bottom"> <p class="First">10</p> </td><td align="center" class="Botrule Rrule" valign="bottom"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="bottom"> <p class="First">4</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Pharyngitis</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Cardiovascular</span> </p> </td><td class="Botrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Peripheral Edema </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Hepatic/Metabolic/Laboratory/Renal</span> </p> </td><td class="Botrule" valign="top"></td><td class="Botrule Rrule" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Hematuria</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Dysuria</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr class="Last"> <td class="Botrule" colspan="4" valign="top"> <p class="First">* Event coded in WHO-ART dictionary <br/> † No complete alopecia was reported. </p> </td> </tr> </tbody> </table></div>

Clinically relevant adverse reactions in greater than or equal to 2% and less than 5% of the patients in the oxaliplatin injection and fluorouracil/leucovorin combination arm (listed in decreasing order of frequency) were: anxiety, myalgia, erythematous rash, increased sweating, conjunctivitis, weight decrease, dry mouth, rectal hemorrhage, depression, ataxia, ascites, hemorrhoids, muscle weakness, nervousness, tachycardia, abnormal micturition frequency, dry skin, pruritus, hemoptysis, purpura, vaginal hemorrhage, melena, somnolence, pneumonia, proctitis, involuntary muscle contractions, intestinal obstruction, gingivitis, tenesmus, hot flashes, enlarged abdomen, and urinary incontinence.

<div class="scrollingtable"><table width="100%"> <caption> <span>Table 13: Laboratory-Related Adverse Reactions Occurring in ≥5% of Patients with Previously Treated Advanced Colorectal Cancer</span> </caption> <col width="18%"/> <col width="17%"/> <col width="17%"/> <col width="17%"/> <col width="13%"/> <col width="9%"/> <col width="9%"/> <tbody class="Headless"> <tr class="First"> <td align="center" class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"> <p class="First"> <span class="Bold">Laboratory-Related</span> <br/> <span class="Bold">Adverse Reaction</span> </p> </td><td align="center" class="Botrule Rrule Toprule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection and FU/LV N=150</span> </p> </td><td align="center" class="Botrule Rrule Toprule" colspan="2" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection</span> <br/> <span class="Bold">N=153</span> </p> </td><td align="center" class="Botrule Rrule Toprule" colspan="2" valign="top"> <p class="First"> <span class="Bold">FU/LV</span> </p> <p> <span class="Bold">N=142</span> </p> </td> </tr> <tr> <td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All</span> <br/> <span class="Bold">Grades</span> <br/> <span class="Bold">(%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">Grades</span> <br/> <span class="Bold">3-4</span> <br/> <span class="Bold">(%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All</span> <br/> <span class="Bold">Grades</span> <br/> <span class="Bold">(%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">Grades</span> <br/> <span class="Bold">3-4</span> <br/> <span class="Bold">(%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">All</span> <br/> <span class="Bold">Grades</span> <br/> <span class="Bold">(%)</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First"> <span class="Bold">Grades</span> <br/> <span class="Bold">3-4</span> <br/> <span class="Bold">(%)</span> </p> </td> </tr> <tr> <td class="Botrule Lrule" valign="top"> <p class="First"> <span class="Bold">Hematology</span> </p> </td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule Rrule" colspan="2" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Anemia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">81</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">64</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">68</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Leukopenia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">76</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">19</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">13</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">34</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Neutropenia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">73</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">44</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">25</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Thrombocytopenia</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">64</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">30</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">20</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td> </tr> <tr> <td class="Botrule Lrule" valign="top"> <p class="First"> <span class="Bold">Hepatic</span> </p> </td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule" colspan="2" valign="top"></td><td class="Botrule Rrule" colspan="2" valign="top"></td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Increased ALT *  </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">31</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">36</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">28</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Increased AST <span class="Sup">†</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">47</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">54</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">39</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Increased Bilirubin</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">13</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">13</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">22</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6</p> </td> </tr> <tr class="Last"> <td class="Botrule" colspan="7" valign="top"> <p class="First">* Alanine transaminase <br/> † Aspartate transaminase </p> </td> </tr> </tbody> </table></div>

Additional Adverse Reactions

The following adverse reactions were observed across clinical trials.

Intravenous site reactions

Injection site reaction, including redness, swelling, and pain, can occur with oxaliplatin injection. In some cases, skin necrosis has occurred with extravasation.

PRES

PRES occurred in less than 0.1% of patients .

Pulmonary fibrosis and interstitial lung disease

Pulmonary fibrosis, which may be fatal, occurred in less than 1% of patients.

The following adverse reactions have been identified during postapproval use of oxaliplatin injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

QT interval prolongation and ventricular arrhythmias can occur with oxaliplatin injection [see Warnings and Precautions ( 5.7)] . Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval.

Because platinum-containing species are eliminated primarily through the kidney, clearance of these products may be decreased by coadministration of potentially nephrotoxic compounds [see Clinical Pharmacology ( 12.3)]. Avoid coadministration of oxaliplatin injection with medicinal products known to cause nephrotoxicity.

Prolonged prothrombin time and INR occasionally associated with hemorrhage have been reported in patients who received oxaliplatin injection with fluorouracil/leucovorin while on anticoagulants [see Warnings and Precautions ( 5.9), Adverse Reactions ( 6.2)]. Increase frequency of monitoring in patients who are receiving oxaliplatin injection with fluorouracil/leucovorin and oral anticoagulants.

Risk Summary

Based on its direct interaction with DNA, oxaliplatin injection can cause fetal harm when administered to a pregnant woman. The available human data do not establish the presence or absence of major birth defects or miscarriage related to the use of oxaliplatin injection. Reproductive toxicity studies demonstrated adverse effects on embryo-fetal development in rats at maternal doses that were below the recommended human dose based on body surface area (see Data). Advise a pregnant woman of the potential risk to a fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal data

Pregnant rats were administered oxaliplatin at less than one-tenth the recommended human dose based on body surface area during gestation days (GD)1-5 (preimplantation), GD 6-10, or GD 11-16 (during organogenesis). Oxaliplatin caused developmental mortality (increased early resorptions) when administered on days GD 6-10 and GD 11-16 and adversely affected fetal growth (decreased fetal weight, delayed ossification) when administered on days GD 6-10.

Risk Summary

There are no data on the presence of oxaliplatin or its metabolites in human or animal milk or its effects on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with oxaliplatin injection and for 3 months after the final dose.

Pregnancy Testing

Verify pregnancy status in females of reproductive potential prior to initiating oxaliplatin injection [see Use in Specific Populations ( 8.1)] .

Contraception

Oxaliplatin Injection can cause embryo-fetal harm when administered to a pregnant woman [see Use in Specific Populations ( 8.1)].

Females

Advise female patients of reproductive potential to use effective contraception while receiving oxaliplatin injection and for 9 months after the final dose.

Males

Based on its mechanism action as a genotoxic drug, advise males with female partners of reproductive potential to use effective contraception while receiving oxaliplatin injection and for 6 months after the final dose [see Nonclinical Toxicology ( 13.1)] .

Infertility

Based on animal studies, oxaliplatin injection may impair fertility in males and females [see Nonclinical Toxicology ( 13.1)].

The safety and effectiveness of oxaliplatin in pediatrics have not been established. Safety and effectiveness were assessed across 4 open-label studies in 235 patients aged 7 months to 22 years with solid tumors.

In a multicenter, open-label, non-comparative, non-randomized study (ARD5531), oxaliplatin was administered to 43 patients with refractory or relapsed malignant solid tumors, mainly neuroblastoma and osteosarcoma. The dose limiting toxicity (DLT) was sensory neuropathy at a dose of 110 mg/m 2. The main adverse reactions were: paresthesia (60%, grade 3-4: 7%), fever (40%, grade 3-4: 7%) and thrombocytopenia (40%, grade 3-4: 27%). No responses were observed.

In an open-label non-randomized study (DFI7434), oxaliplatin was administered to 26 pediatric patients with metastatic or unresectable solid tumors, mainly neuroblastoma and ganglioneuroblastoma. The DLT was sensory neuropathy at a dose of 160 mg/m 2. No responses were observed.

In an open-label, single-agent study (ARD5021), oxaliplatin was administered to 43 pediatric patients with recurrent or refractory embryonal CNS tumors. The most common adverse reactions reported were: leukopenia (67%, grade 3-4: 12%), anemia (65%, grade 3-4: 5%), thrombocytopenia (65%, grade 3-4: 26%), vomiting (65%, grade 3-4: 7%), neutropenia (58%, grade 3-4: 16%), and sensory neuropathy (40%, grade 3-4: 5%).

In an open-label single-agent study (ARD5530), oxaliplatin was administered to 123 pediatric patients with recurrent solid tumors, including neuroblastoma, osteosarcoma, Ewing sarcoma or peripheral PNET, ependymoma, rhabdomyosarcoma, hepatoblastoma, high grade astrocytoma, brain stem glioma, low grade astrocytoma, malignant germ cell tumor and other tumors. The most common adverse reactions reported were: sensory neuropathy (52%, grade 3-4: 12%), thrombocytopenia (37%, grade 3-4: 17%), anemia (37%, grade 3-4: 9%), vomiting (26%, grade 3-4: 4%), increased ALT (24%, grade 3-4: 6%), increased AST (24%, grade 3-4: 2%), and nausea (23%, grade 3-4: 3%).

The pharmacokinetic parameters of ultrafiltrable platinum were evaluated in 105 pediatric patients during the first cycle. The mean clearance in pediatric patients estimated by the population pharmacokinetic analysis was 4.7 L/h (%CV, 41%). Mean platinum pharmacokinetic parameters in ultrafiltrate were C maxof 0.75 ± 0.24 mcg/mL, AUC 0-48hof 7.52 ± 5.07 mcg∙h/mL and AUC infof 8.83 ± 1.57 mcg∙h/mL at 85 mg/m 2 of oxaliplatin and C maxof 1.10 ± 0.43 mcg/mL, AUC 0-48hof 9.74 ± 2.52 mcg∙h/mL and AUC infof 17.3 ± 5.34 mcg∙h/mL at 130 mg/m 2 of oxaliplatin.

In the adjuvant treatment trial [see Clinical Studies ( 14.1)] , 400 patients who received oxaliplatin injection with fluorouracil/leucovorin were greater than or equal to 65 years. The effect of oxaliplatin injection in patients greater than or equal to 65 years was not conclusive. Patients greater than or equal to 65 years receiving oxaliplatin injection experienced more diarrhea and grade 3-4 neutropenia (45% vs 39%) compared to patients less than 65 years.

In the previously untreated advanced colorectal cancer trial [see Clinical Studies ( 14.2)] , 99 patients who received oxaliplatin injection with fluorouracil and leucovorin were greater than or equal to 65 years. The same efficacy improvements in response rate, time to tumor progression, and overall survival were observed in the greater than or equal to 65 years patients as in the overall study population. Adverse reactions were similar in patients less than 65 and greater than or equal to 65 years, but older patients may have been more susceptible to diarrhea, dehydration, hypokalemia, leukopenia, fatigue, and syncope.

In the previously treated advanced colorectal cancer trial [see Clinical Studies ( 14.3)] , 55 patients who received oxaliplatin injection with fluorouracil and leucovorin were greater than or equal to 65 years. No overall differences in effectiveness were observed between these patients and younger adults. Adverse reactions were similar in patients less than 65 and greater than or equal to 65 years, but older patients may have been more susceptible to diarrhea, dehydration, hypokalemia, and fatigue.

No significant effect of age on the clearance of ultrafiltrable platinum has been observed [see Clinical Pharmacology ( 12.3)] .

The AUC of unbound platinum in plasma ultrafiltrate was increased in patients with renal impairment [see Clinical Pharmacology ( 12.3)] . No dose reduction is recommended for patients with mild (creatinine clearance 50 to 79 mL/min) or moderate (creatinine clearance 30 to 49 mL/min) renal impairment, calculated by Cockcroft-Gault equation. Reduce the dose of oxaliplatin injection in patients with severe renal impairment (creatinine clearance less than 30 mL/min) [see Dosage and Administration ( 2.3)].

The maximum dose of oxaliplatin that has been administered in a single infusion is 825 mg. Several cases of overdoses have been reported with oxaliplatin injection. Adverse reactions observed following an overdosage were grade 4 thrombocytopenia (less than 25,000/mm 3) without bleeding, anemia, sensory neuropathy (including paresthesia, dysesthesia, laryngospasm and facial muscle spasms), gastrointestinal disorders (including nausea, vomiting, stomatitis, flatulence, abdomen enlarged and grade 4 intestinal obstruction), grade 4 dehydration, dyspnea, wheezing, chest pain, respiratory failure, severe bradycardia, and death.

{ "type": "p", "children": [], "text": "The maximum dose of oxaliplatin that has been administered in a single infusion is 825 mg. Several cases of overdoses have been reported with oxaliplatin injection. Adverse reactions observed following an overdosage were grade 4 thrombocytopenia (less than 25,000/mm\n \n 3) without bleeding, anemia, sensory neuropathy (including paresthesia, dysesthesia, laryngospasm and facial muscle spasms), gastrointestinal disorders (including nausea, vomiting, stomatitis, flatulence, abdomen enlarged and grade 4 intestinal obstruction), grade 4 dehydration, dyspnea, wheezing, chest pain, respiratory failure, severe bradycardia, and death.\n\n " }

Closely monitor patients suspected of receiving an overdose, including for the adverse reactions described above and administer appropriate supportive treatment.

{ "type": "p", "children": [], "text": "Closely monitor patients suspected of receiving an overdose, including for the adverse reactions described above and administer appropriate supportive treatment." }

Oxaliplatin is a platinum-based drug with the molecular formula C 8H 14N 2O 4Pt and the chemical name of cis-[(1 R, 2 R)-1, 2-cyclohexanediamine- N, N'] [oxalato (2-)- O, O'] platinum. Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a leaving group.

{ "type": "p", "children": [], "text": "Oxaliplatin is a platinum-based drug with the molecular formula C\n \n 8H\n \n 14N\n \n 2O\n \n 4Pt and the chemical name of\n \n cis-[(1\n \n R, 2\n \n R)-1, 2-cyclohexanediamine-\n \n N,\n \n N'] [oxalato (2-)-\n \n O,\n \n O'] platinum. Oxaliplatin is an organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a leaving group.\n\n " }

The molecular weight is 397.3. Oxaliplatin is slightly soluble in water at 6 mg/mL, very slightly soluble in methanol, and practically insoluble in ethanol and acetone.

{ "type": "p", "children": [], "text": "The molecular weight is 397.3. Oxaliplatin is slightly soluble in water at 6 mg/mL, very slightly soluble in methanol, and practically insoluble in ethanol and acetone." }

Oxaliplatin Injection USP, for intravenous use is supplied in vials containing 50 mg or 100 mg of oxaliplatin as a sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL. Water for Injection, USP is present as an inactive ingredient.

{ "type": "p", "children": [], "text": "Oxaliplatin Injection USP, for intravenous use is supplied in vials containing 50 mg or 100 mg of oxaliplatin as a sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL. Water for Injection, USP is present as an inactive ingredient." }

Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7positions of two adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by an intervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.

In vivo studies have shown antitumor activity of oxaliplatin against colon carcinoma. In combination with fluorouracil, oxaliplatin exhibits in vitro and in vivo antiproliferative activity greater than either compound alone in several tumor models (HT29 [colon], GR [mammary], and L1210 [leukemia]).

A pharmacodynamic relationship between platinum ultrafiltrate levels and clinical safety and effectiveness has not been established.

The reactive oxaliplatin derivatives are present as a fraction of the unbound platinum in plasma ultrafiltrate. After a single 2-hour intravenous infusion of oxaliplatin injection at a dose of 85 mg/m 2, pharmacokinetic parameters expressed as ultrafilterable platinum were C maxof 0.814 mcg/mL and volume of distribution of 440 L.

Interpatient and intrapatient variability in ultrafilterable platinum exposure (AUC 0-48hr) assessed over 3 cycles was 23% and 6%, respectively.

Distribution

At the end of a 2-hour infusion of oxaliplatin injection, approximately 15% of the administered platinum is present in the systemic circulation. The remaining 85% is rapidly distributed into tissues or eliminated in the urine. The decline of ultrafiltrable platinum levels following oxaliplatin injection administration is triphasic, including two distribution phases (t 1/2α; 0.43 hours and t 1/2β; 16.8 hours).

In patients, plasma protein binding of platinum is irreversible and is greater than 90%. The main binding proteins are albumin and gamma-globulins.

Platinum also binds irreversibly and accumulates (approximately 2-fold) in erythrocytes, where it appears to have no relevant activity. No platinum accumulation was observed in plasma ultrafiltrate following 85 mg/m 2 every two weeks.

Elimination

The decline of ultrafiltrable platinum concentrations from plasma is characterized by a long terminal elimination phase (t 1/2γ; 391 hours).

Metabolism

Oxaliplatin undergoes rapid and extensive nonenzymatic biotransformation. There is no evidence of cytochrome P450-mediated metabolism in vitro.

Up to 17 platinum-containing derivatives have been observed in plasma ultrafiltrate samples from patients, including several cytotoxic species (monochloro DACH platinum, dichloro DACH platinum, and monoaquo and diaquo DACH platinum) and a number of noncytotoxic, conjugated species.

Excretion

The major route of platinum elimination is renal excretion. At five days after a single 2-hour infusion of oxaliplatin injection, urinary elimination accounted for about 54% of the platinum eliminated, with fecal excretion accounting for only about 2%. Platinum was cleared from plasma at a rate (10-17 L/h) that was similar to or exceeded the average human glomerular filtration rate (GFR; 7.5 L/h). The renal clearance of ultrafiltrable platinum is significantly correlated with GFR.

Special Populations

Sex

There was no significant effect of sex on the clearance of ultrafiltrable platinum.

Patients with renal impairment

Patients with normal function (CLcr greater than 80 mL/min) and patients with mild (CLcr=50-80 mL/min) and moderate (CLcr equal to 30-49 mL/min) renal impairment received oxaliplatin injection 85 mg/m 2 and those with severe (CLcr less than 30 mL/min) renal impairment received oxaliplatin injection 65 mg/m 2. Mean dose adjusted AUC of unbound platinum was 40%, 95%, and 342% higher for patients with mild, moderate, and severe renal impairment, respectively, compared to patients with normal renal function. Mean dose adjusted C maxof unbound platinum appeared to be similar among the normal, mild and moderate renal function groups, but was 38% higher in the severe group than in the normal group [see Dosage and Administration ( 2.3)] .

Drug Interaction Studies

No pharmacokinetic interaction between oxaliplatin injection 85 mg/m 2 and infusional fluorouracil has been observed in patients treated every 2 weeks, but increases of fluorouracil plasma concentrations by approximately 20% have been observed with doses of 130 mg/m 2 of oxaliplatin injection administered every 3 weeks.

In vitro platinum was not displaced from plasma proteins by the following medications: erythromycin, salicylate, sodium valproate, granisetron, and paclitaxel.

In vitro oxaliplatin does not inhibit human cytochrome P450 isoenzymes.

Long-term animal studies have not been performed to evaluate the carcinogenic potential of oxaliplatin. Oxaliplatin was not mutagenic to bacteria (Ames test) but was mutagenic to mammalian cells in vitro (L5178Y mouse lymphoma assay). Oxaliplatin was clastogenic both in vitro (chromosome aberration in human lymphocytes) and in vivo (mouse bone marrow micronucleus assay).

In a fertility study, male rats were given oxaliplatin at 0, 0.5, 1, or 2 mg/kg/day for five days every 21 days for a total of three cycles prior to mating with females that received two cycles of oxaliplatin on the same schedule. A dose of 2 mg/kg/day (less than one-seventh the recommended human dose on a body surface area basis) did not affect pregnancy rate, but resulted in 97% postimplantation loss (increased early resorptions, decreased live fetuses, decreased live births), and delayed growth (decreased fetal weight).

Testicular damage, characterized by degeneration, hypoplasia, and atrophy, was observed in dogs administered oxaliplatin at 0.75 mg/kg/day (approximately one-sixth of the recommended human dose on a body surface area basis) x 5 days every 28 days for three cycles. A no effect level was not identified.

The efficacy of oxaliplatin injection in combination with fluorouracil (FU)/leucovorin (LV) was evaluated in an international, multicenter, randomized (1:1) trial (The Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer [MOSAIC], NCT00275210) in patients with stage II (Dukes' B2) or III (Dukes' C) colon cancer who had undergone complete resection of the primary tumor. Patients were randomized to receive oxaliplatin injection with fluorouracil/leucovorin or fluorouracil/leucovorin alone for a total of 6 months (i.e., 12 cycles). Table 14 shows the dosing regimens for the two arms.

Eligible patients were between 18 and 75 years of age, had histologically proven stage II (T 3-T 4N0 M0; Dukes' B2) or III (any T N 1-2M0; Dukes' C) colon carcinoma (with the inferior pole of the tumor above the peritoneal reflection, i.e., greater than or equal to 15 cm from the anal margin) and had undergone (within 7 weeks prior to randomization) complete resection of the primary tumor without gross or microscopic evidence of residual disease and carcino-embyrogenic antigen (CEA) less than 10 ng/mL. Additional eligibility criteria were no prior chemotherapy, immunotherapy or radiotherapy; Eastern Cooperative Oncology Group performance status of 0, 1, or 2 (Karnofsky Performance Status greater than or equal to 60%); no pre-existing neuropathy; and absolute neutrophil count (ANC) greater than or equal to 1.5x10 9/L, platelets greater than or equal to 100 x 10 9/L, serum creatinine less than or equal to 1.25 x upper limit normal (ULN), total bilirubin less than 2 x ULN, and aspartate transaminase (AST)/alanine transaminase (ALT) less than 2 x ULN. The major efficacy outcome was 3-year disease-free survival (DFS).

<div class="scrollingtable"><table width="100%"> <caption> <span>Table 14: Dosing Regimens in Adjuvant Treatment Study</span> </caption> <col width="28%"/> <col width="52%"/> <col width="20%"/> <tbody class="Headless"> <tr class="First"> <td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Treatment Arm</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Dose</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Regimen</span> </p> </td> </tr> <tr> <td align="center" class="Botrule Lrule Rrule" valign="top"> <p class="First">Oxaliplatin Injection + FU/LV(FOLFOX4) (N =1123)</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Day 1: Oxaliplatin Injection: 85 mg/m <span class="Sup">2</span>(2-hour infusion) + LV: 200 mg/m <span class="Sup">2</span>(2-hour infusion), followed by FU: 400 mg/m <span class="Sup">2</span>(bolus), 600 mg/m <span class="Sup">2</span>(22-hour infusion) <br/> Day 2: LV: 200 mg/m <span class="Sup">2</span>(2-hour infusion), followed by FU: 400 mg/m <span class="Sup">2</span>(bolus), 600 mg/m <span class="Sup">2</span>(22-hour infusion) </p> </td><td class="Botrule Rrule" valign="top"> <p class="First">every 2 weeks 12 cycles</p> </td> </tr> <tr class="Last"> <td align="center" class="Botrule Lrule Rrule" valign="top"> <p class="First">FU/LV (N=1123)</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Day 1: LV: 200 mg/m <span class="Sup">2</span>(2-hour infusion), followed by FU: 400 mg/m <span class="Sup">2</span>(bolus), 600 mg/m <span class="Sup">2</span>(22-hour infusion) <br/> Day 2: LV: 200 mg/m <span class="Sup">2</span>(2-hour infusion), followed by FU: 400 mg/m <span class="Sup">2</span>(bolus), 600 mg/m <span class="Sup">2</span>(22-hour infusion) </p> </td><td class="Botrule Rrule" valign="top"> <p class="First">every 2 weeks 12 cycles</p> </td> </tr> </tbody> </table></div>

There were 2246 patients enrolled, of whom 1347 (60%) had Stage III disease. Tables 15 and 16 show the baseline characteristics and exposure to oxaliplatin injection.

<div class="scrollingtable"><table width="96%"> <caption> <span>Table 15: Baseline Characteristics in Adjuvant Treatment Study</span> </caption> <col width="52%"/> <col width="31%"/> <col width="17%"/> <tbody class="Headless"> <tr class="First"> <td class="Botrule Lrule Rrule Toprule" valign="top"></td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection + Infusional FU/LV</span> <br/> <span class="Bold">N=1123</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Infusional FU/LV N=1123</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Sex: Male (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">56.1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">52.4</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">        Female (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">43.9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">47.6</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Median age (years)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">61.0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">60.0</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   &lt;65 years of age (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">64.4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">66.2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   ≥65 years of age (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">35.6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">33.8</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First">KPS (%)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   100</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">29.7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">30.5</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   90</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">52.2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">53.9</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   80</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4.4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3.3</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   70</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">13.2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11.9</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   ≤60</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0.6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0.4</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First">Primary site (%)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   Colon including cecum</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">54.6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">54.4</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   Sigmoid</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">31.9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">33.8</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   Recto sigmoid</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">12.9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">10.9</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   Other including rectum</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0.6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0.9</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First">Bowel obstruction (%)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   Yes</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">17.9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">19.3</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First">Perforation (%)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   Yes</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6.9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6.9</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First">Stage at Randomization (%)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   II (T=3,4 N=0, M=0)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">40.1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">39.9</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   III (T=any, N=1,2, M=0)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">59.6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">59.3</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   IV (T=any, N=any, M=1)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0.4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0.8</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First">Staging – T (%)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   T1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0.5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0.7</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   T2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4.5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4.8</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   T3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">76.0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">75.9</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   T4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">19.0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">18.5</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First">Staging – N (%)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   N0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">40.2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">39.9</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   N1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">39.4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">39.4</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   N2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">20.4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">20.7</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First">Staging – M (%)</p> </td> </tr> <tr class="Last"> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   M1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0.4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0.8</p> </td> </tr> </tbody> </table></div>

<div class="scrollingtable"><table width="96%"> <caption> <span>Table 16: Exposure to Oxaliplatin Injection in Adjuvant Treatment Study</span> </caption> <col width="55%"/> <col width="20%"/> <col width="25%"/> <tbody class="Headless"> <tr class="First"> <td class="Botrule Lrule Rrule Toprule" valign="top"></td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection + Infusional FU/LV N=1108</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Infusional FU/LV N=1111</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First">Median Relative Dose Intensity (%)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   FU</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">84.4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">97.7</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   Oxaliplatin Injection</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">80.5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">N/A</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Median Number of Cycles</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">12</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">12</p> </td> </tr> <tr class="Last"> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Median Number of Cycles with Oxaliplatin Injection</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">N/A</p> </td> </tr> </tbody> </table></div>

The median duration of follow-up was approximately 77 months. In the overall and the stage III colon cancer populations, DFS was statistically significantly improved in the oxaliplatin injection-containing arm compared to fluorouracil/leucovorin alone; however, a statistically significant improvement in DFS was not observed in Stage II patients. No significant differences in overall survival (OS) were detected in the overall population or those with Stage III disease. Table 17 and Figures 1 and 2 summarize the 5-year DFS rates in the overall randomized population and in patients with stage II and III disease based on an intention-to-treat (ITT) analysis.

<div class="scrollingtable"><table width="98%"> <caption> <span>Table 17: Summary of DFS Analysis in Adjuvant Treatment Study – ITT Population</span> </caption> <col width="51%"/> <col width="28%"/> <col width="21%"/> <tbody class="Headless"> <tr class="First"> <td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Parameter</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection + Infusional FU/LV</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Infusional FU/LV</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Overall</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Number of patients</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1123</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1123</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Number of events – relapse or death (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">304 (27.1)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">360 (32.1)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">5-yr Disease-free survival % (95% CI)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">73.3 (70.7, 76.0)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">67.4 (64.6, 70.2)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   Hazard ratio (95% CI)</p> </td><td align="center" class="Botrule Rrule" colspan="2" valign="top"> <p class="First">0.80 (0.68, 0.93)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   Stratified Log rank test</p> </td><td align="center" class="Botrule Rrule" colspan="2" valign="top"> <p class="First">p=0.003</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Stage III (Dukes' C)</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Number of patients</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">672</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">675</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Number of events –relapse or death (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">226 (33.6)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">271 (40.1)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">5-yr Disease-free survival % (95% CI)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">66.4 (62.7, 70.0)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">58.9 (55.2, 62.7)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   Hazard ratio (95% CI)</p> </td><td align="center" class="Botrule Rrule" colspan="2" valign="top"> <p class="First">0.78 (0.65, 0.93)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   Log rank test</p> </td><td align="center" class="Botrule Rrule" colspan="2" valign="top"> <p class="First">p=0.005</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Stage II (Dukes' B2)</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Number of patients</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">451</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">448</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Number of events – relapse or death (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">78 (17.3)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">89 (19.9)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">5-yr Disease-free survival % (95% CI)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">83.7 (80.2, 87.1)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">79.9 (76.2, 83.7)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">    Hazard ratio (95% CI)</p> </td><td align="center" class="Botrule Rrule" colspan="2" valign="top"> <p class="First">0.84 (0.62, 1.14)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">    Log rank test</p> </td><td align="center" class="Botrule Rrule" colspan="2" valign="top"> <p class="First">p=0.258</p> </td> </tr> <tr class="Last"> <td class="Botrule" colspan="3" valign="top"> <p class="First">A hazard ratio of less than 1 favors Oxaliplatin Injection + Infusional FU/LV <br/> Data cut off for disease-free survival June 1, 2006 </p> </td> </tr> </tbody> </table></div>

Figure 1: Kaplan-Meier Curves of Disease-Free Survival (cutoff: 1 June 2006) in Adjuvant Treatment Trial – ITT Population

Figure 2: Kaplan-Meier Curves of Disease-Free Survival in Stage III Patients (cutoff: 1 June 2006) in Adjuvant Treatment Trial – ITT Population

Table 18 summarizes the OS results in the overall randomized population and in patients with stage II and III disease, based on the ITT analysis.

<div class="scrollingtable"><table width="86%"> <caption> <span>Table 18: Summary of OS Analysis in Adjuvant Treatment - ITT Population</span> </caption> <col width="33%"/> <col width="27%"/> <col width="39%"/> <tbody class="Headless"> <tr class="First"> <td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Parameter</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection + Infusional FU/LV</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Infusional FU/LV</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Overall</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Number of patients</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1123</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1123</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Number of death events (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">245 (21.8)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">283 (25.2)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">    Hazard ratio (95% CI)</p> </td><td align="center" class="Botrule Rrule" colspan="2" valign="top"> <p class="First">0.84 (0.71, 1.00)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Stage III (Dukes' C)</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Number of patients</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">672</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">675</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Number of death events (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">182 (27.1)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">220 (32.6)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   Hazard ratio (95% CI)</p> </td><td align="center" class="Botrule Rrule" colspan="2" valign="top"> <p class="First">0.80 (0.65, 0.97)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="3" valign="top"> <p class="First"> <span class="Bold">Stage II (Dukes' B2)</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Number of patients</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">451</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">448</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Number of death events (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">63 (14.0)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">63 (14.1)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">    Hazard ratio (95% CI)</p> </td><td align="center" class="Botrule Rrule" colspan="2" valign="top"> <p class="First">1.00 (0.70, 1.41)</p> </td> </tr> <tr class="Last"> <td class="Botrule" colspan="3" valign="top"> <p class="First">A hazard ratio of less than 1 favors Oxaliplatin Injection + Infusional FU/LV <br/> Data cut off for overall survival January 16, 2007 </p> </td> </tr> </tbody> </table></div>

The efficacy of oxaliplatin injection in combination with fluorouracil (FU)/leucovorin (LV) was evaluated in a North American, multicenter, open-label, randomized, active-controlled trial (A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients with Advanced Adenocarcinoma of the Colon and Rectum; NCT00003594). The trial included 7 arms at different times during its conduct, four of which were closed due to either changes in the standard of care, toxicity, or simplification. During the trial, the control arm was changed to irinotecan with fluorouracil/leucovorin.

The results reported below compared the efficacy of oxaliplatin injection with fluorouracil/leucovorin and oxaliplatin injection with irinotecan to an approved control regimen of irinotecan with fluorouracil/leucovorin in 795 concurrently randomized patients previously untreated for locally advanced or metastatic colorectal cancer. Table 19 presents the dosing regimens for the three arms. After completion of enrollment, the dose of irinotecan with fluorouracil/leucovorin was decreased due to toxicity.

Eligible patients were at least 18 years of age; had known locally advanced, locally recurrent, or metastatic colorectal adenocarcinoma not curable by surgery or amenable to radiation therapy; with an Eastern Cooperative Oncology Group (ECOG) performance status ≤0, 1, or 2. Patients had to have absolute neutrophil count (ANC) greater than or equal to 1.5 × 10 9/L, platelets greater than or equal to 100 x 10 9/L, hemoglobin greater than or equal to 9.0 g/dL, creatinine less than or equal to 1.5 x upper limit of normal (ULN), total bilirubin less than or equal to 1.5 mg/dL, aspartate transaminase (AST) less than or equal to  5 x ULN, and alkaline phosphatase less than or equal to 5 x ULN. Patients may have received adjuvant treatment for resected Stage II or III disease without recurrence within 12 months. Randomization was stratified by ECOG performance status (0, 1 vs 2), prior adjuvant chemotherapy (yes vs no), prior immunotherapy (yes vs no), and age (less than 65 vs greater than or equal to 65 years). Although no post study treatment was specified in the protocol, 65% to 72% of patients received additional post study chemotherapy after study treatment discontinuation on all arms. Fifty-eight percent of patients on the oxaliplatin injection with fluorouracil/leucovorin arm received an irinotecan-containing regimen and 23% of patients on the irinotecan with fluorouracil/leucovorin arm received an oxaliplatin-containing regimen. The main efficacy outcome measure was 3-year disease-free survival (DFS) and additional efficacy outcome measures were overall survival (OS).

<div class="scrollingtable"><table width="100%"> <caption> <span>Table 19: Dosing Regimens for Previously Untreated Advanced Colorectal Cancer Clinical Trial</span> </caption> <col width="28%"/> <col width="58%"/> <col width="14%"/> <tbody class="Headless"> <tr class="First"> <td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Treatment Arm</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Dose</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Regimen</span> </p> </td> </tr> <tr> <td align="center" class="Botrule Lrule Rrule" valign="top"> <p class="First">Oxaliplatin Injection+ FU/LV (FOLFOX4) (N=267)</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Day 1: Oxaliplatin Injection: 85 mg/m <span class="Sup">2</span>(2-hour infusion) + LV 200 mg/m <span class="Sup">2</span>(2-hour infusion), followed by FU: 400 mg/m <span class="Sup">2</span>(bolus), 600 mg/m <span class="Sup">2</span>(22-hour infusion) <br/> Day 2: LV 200 mg/m <span class="Sup">2</span>(2-hour infusion), followed by FU: 400 mg/m <span class="Sup">2</span>(bolus), 600 mg/m <span class="Sup">2</span>(22-hour infusion) </p> </td><td class="Botrule Rrule" valign="top"> <p class="First">every 2 weeks</p> </td> </tr> <tr> <td align="center" class="Botrule Lrule Rrule" valign="top"> <p class="First">Irinotecan + <br/> FU/LV <br/> (IFL) <br/> (N=264) </p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Day 1: irinotecan 125 mg/m <span class="Sup">2</span>as a 90-min infusion + LV 20 mg/m <span class="Sup">2</span>as a 15-min infusion or intravenous push, followed by FU 500 mg/m <span class="Sup">2</span>intravenous bolus weekly x 4 </p> </td><td class="Botrule Rrule" valign="top"> <p class="First">every 6 weeks</p> </td> </tr> <tr class="Last"> <td align="center" class="Botrule Lrule Rrule" valign="top"> <p class="First">Oxaliplatin Injection+Irinotecan <br/> (IROX) <br/> (N=264) </p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Day 1: Oxaliplatin Injection: 85 mg/m <span class="Sup">2</span>intravenous <br/> (2-hour infusion) + irinotecan 200 mg/m <span class="Sup">2</span>intravenous over 30 minutes </p> </td><td class="Botrule Rrule" valign="top"> <p class="First">every 3 weeks</p> </td> </tr> </tbody> </table></div>

Table 20 presents the baseline characteristics.

<div class="scrollingtable"><table width="94%"> <caption> <span>Table 20: Baseline Characteristics for Previously Untreated Advanced Colorectal Cancer Clinical Trial</span> </caption> <col width="29%"/> <col width="22%"/> <col width="21%"/> <col width="28%"/> <tbody class="Headless"> <tr class="First"> <td class="Botrule Lrule Rrule Toprule" valign="bottom"></td><td align="center" class="Botrule Rrule Toprule" valign="bottom"> <p class="First"> <span class="Bold">Oxaliplatin Injection + FU/LV N=267</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="bottom"> <p class="First"> <span class="Bold">Irinotecan + FU/LV N=264</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="bottom"> <p class="First"> <span class="Bold">Oxaliplatin Injection + Irinotecan N=264</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Sex: Male (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">58.8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">65.2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">61.0</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">        Female (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">41.2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">34.8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">39.0</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Median age (years)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">61.0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">61.0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">61.0</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  &lt;65 years of age (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">61</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">62</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">63</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  ≥65 years of age (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">39</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">38</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">37</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="4" valign="top"> <p class="First">ECOG (%)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   0-1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">94.4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">95.5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">94.7</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">   2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5.6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4.5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5.3</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="4" valign="top"> <p class="First">Involved organs (%)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  Colon only</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0.7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0.8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0.4</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  Liver only</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">39.3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">44.3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">39.0</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  Liver + other</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">41.2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">38.6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">40.9</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  Lung only</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6.4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3.8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5.3</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  Other (including lymph nodes)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11.6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">11.0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">12.9</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  Not reported</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0.7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1.5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1.5</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Prior radiation (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3.0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1.5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3.0</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Prior surgery (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">74.5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">79.2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">81.8</p> </td> </tr> <tr class="Last"> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Prior adjuvant (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">15.7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">14.8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">15.2</p> </td> </tr> </tbody> </table></div>

The median number of cycles administered per patient was 10 (23.9 weeks) for the oxaliplatin injection plus fluorouracil/leucovorin regimen, 4 (23.6 weeks) for the irinotecan plus fluorouracil/leucovorin regimen, and 7 (21.0 weeks) for the oxaliplatin injection plus irinotecan regimen.

Patients who received oxaliplatin injection with fluorouracil/leucovorin had a significantly longer time to tumor progression based on investigator assessment, longer OS, and a significantly higher confirmed response rate based on investigator assessment compared to patients who received irinotecan with fluorouracil/leucovorin. Efficacy results are summarized in Table 21 and Figure 3.

<div class="scrollingtable"><table width="96%"> <caption> <span>Table 21: Efficacy Results for Previously Untreated Advanced Colorectal Cancer Trial</span> </caption> <col width="37%"/> <col width="20%"/> <col width="15%"/> <col width="28%"/> <tbody class="Headless"> <tr class="First"> <td class="Botrule Lrule Rrule Toprule" valign="bottom"></td><td align="center" class="Botrule Rrule Toprule" valign="bottom"> <p class="First"> <span class="Bold">Oxaliplatin Injection + FU/LV N=267</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="bottom"> <p class="First"> <span class="Bold">Irinotecan + FU/LV N=264</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="bottom"> <p class="First"> <span class="Bold">Oxaliplatin Injection + Irinotecan N=264</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="4" valign="top"> <p class="First"> <span class="Bold">Survival (ITT)</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Number of deaths (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">155 (58.1)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">192 (72.7)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">175 (66.3)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Median survival (months)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">19.4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">14.6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">17.6</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  Hazard ratio (95% CI) *</p> </td><td align="center" class="Botrule Rrule" colspan="2" valign="top"> <p class="First">0.65 (0.53, 0.80) <span class="Sup">†</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">-</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  P-value</p> </td><td align="center" class="Botrule Rrule" colspan="2" valign="top"> <p class="First">&lt;0.0001 <span class="Sup">†</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">-</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="4" valign="top"> <p class="First"> <span class="Bold">TTP (ITT, investigator assessment)</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Percentage of progressors</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">82.8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">81.8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">89.4</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Median TTP (months)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">8.7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6.9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">6.5</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  Hazard ratio (95%CI) *</p> </td><td align="center" class="Botrule Rrule" colspan="2" valign="top"> <p class="First">0.74 (0.61, 0.89) <span class="Sup">†</span> </p> </td><td class="Botrule Rrule" valign="top"> <p class="First">-</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  P-value</p> </td><td align="center" class="Botrule Rrule" colspan="2" valign="top"> <p class="First">0.0014 <span class="Sup">†</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">-</p> </td> </tr> <tr> <td class="Botrule Lrule" colspan="4" valign="top"> <p class="First"> <span class="Bold">Response Rate (investigator assessment) <span class="Sup">‡</span></span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Patients with measurable disease</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">210</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">212</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">215</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  Complete response, N (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">13 (6.2)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5 (2.4)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7 (3.3)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  Partial response, N (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">82 (39.0)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">64 (30.2)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">67 (31.2)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  Complete and partial response, N (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">95 (45.2)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">69 (32.5)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">74 (34.4)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  95% CI</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">(38.5, 52.0)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">(26.2, 38.9)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">(28.1, 40.8)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  P-value</p> </td><td align="center" class="Botrule Rrule" colspan="2" valign="top"> <p class="First">0.0080 <span class="Sup">†</span> </p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">-</p> </td> </tr> <tr class="Last"> <td class="Botrule" colspan="4" valign="top"> <p class="First">* A hazard ratio of less than 1 favors Oxaliplatin Injection + Infusional FU/LV.</p> <p>† Compared to irinotecan plus fluorouracil/leucovorin (IFL) arm</p> <p>‡ Based on all patients with measurable disease at baseline. <br/> The numbers in the response rate and TTP analysis are based on unblinded investigator assessment. </p> </td> </tr> </tbody> </table></div>

Figure 3: Kaplan-Meier Curves for Overall Survival in Previously Untreated Advanced Colorectal Cancer Trial

In descriptive subgroup analyses, the improvement in overall survival (OS) for oxaliplatin injection with fluorouracil/leucovorin compared to irinotecan with fluorouracil/leucovorin appeared to be maintained across age groups, prior adjuvant treatment, number of organs involved and both sexes; however, the effect appeared larger among women than men.

The efficacy of oxaliplatin injection in combination with fluorouracil (FU)/leucovorin (LV) was evaluated in a multicenter, open-label, randomized, three-arm controlled trial was conducted in the US and Canada in patients with advanced colorectal cancer who had relapsed/progressed during or within 6 months of first-line treatment with bolus fluorouracil/leucovorin and irinotecan (A multicenter, open-label, randomized, three-arm study of 5-fluorouracil (5-FU) + leucovorin (LV) or oxaliplatin or a combination of 5-FU/LV + oxaliplatin as second-line treatment of metastatic colorectal carcinoma: NCT00008281). Patients were randomized to one of three regimens; the dosing regimens are presented in Table 22. Eligible patients were at least 18 years of age, had unresectable, measurable, histologically proven colorectal adenocarcinoma, with a Karnofsky performance status (KPS) greater than 50%. Patients had to have aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase less than or equal to 2x upper limit of normal (ULN), unless liver metastases were present and documented at baseline by CT or MRI scan, in which case less than or equal to 5x ULN was permitted. Prior radiotherapy was permitted if it had been completed at least 3 weeks before randomization. The main efficacy outcome measure was 3-year disease-free survival (DFS) and an additional outcome measure was overall survival (OS).

<div class="scrollingtable"><table width="100%"> <caption> <span>Table 22: Dosing Regimens in Refractory and Relapsed Colorectal Cancer Trial</span> </caption> <col width="27%"/> <col width="52%"/> <col width="21%"/> <tbody class="Headless"> <tr class="First"> <td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Treatment Arm</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Dose</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Regimen</span> </p> </td> </tr> <tr> <td align="center" class="Botrule Lrule Rrule" valign="top"> <p class="First">Oxaliplatin Injection + FU/LV (N =152)</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Day 1: Oxaliplatin Injection: 85 mg/m <span class="Sup">2</span>(2-hour infusion) + LV 200 mg/m <span class="Sup">2</span>(2-hour infusion), followed by FU: 400 mg/m <span class="Sup">2</span>(bolus), 600 mg/m <span class="Sup">2</span>(22-hour infusion) <br/> Day 2: LV 200 mg/m <span class="Sup">2</span>(2-hour infusion), followed by FU: 400 mg/m <span class="Sup">2</span>(bolus), 600 mg/m <span class="Sup">2</span>(22-hour infusion) </p> </td><td class="Botrule Rrule" valign="top"> <p class="First">every 2 weeks</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">FU/LV (N=151)</p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Day 1: LV 200 mg/m <span class="Sup">2</span>(2-hour infusion), followed by FU: 400 mg/m <span class="Sup">2</span>(bolus), 600 mg/m <span class="Sup">2</span>(22-hour infusion) <br/> Day 2: LV 200 mg/m <span class="Sup">2</span>(2-hour infusion), followed by FU: 400 mg/m <span class="Sup">2</span>(bolus), 600 mg/m <span class="Sup">2</span>(22-hour infusion) </p> </td><td class="Botrule Rrule" valign="top"> <p class="First">every 2 weeks</p> </td> </tr> <tr class="Last"> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Oxaliplatin Injection <br/> (N=156) </p> </td><td class="Botrule Rrule" valign="top"> <p class="First">Day 1: Oxaliplatin Injection 85 mg/m <span class="Sup">2</span>(2-hour infusion) </p> </td><td class="Botrule Rrule" valign="top"> <p class="First">every 2 weeks</p> </td> </tr> </tbody> </table></div>

Patients must have had at least one unidimensional lesion measuring greater than or equal to 20 mm using conventional CT or MRI scans or greater than or equal to 10 mm using a spiral CT scan. Tumor response and progression were assessed every 3 cycles (6 weeks) using the Response Evaluation Criteria in Solid Tumors (RECIST) until radiological documentation of progression or for 13 months following the first dose of study drug(s), whichever came first. Confirmed responses were based on two tumor assessments separated by at least 4 weeks. Baseline characteristics are shown in Table 23.

<div class="scrollingtable"><table width="91%"> <caption> <span>Table 23: Baseline Characteristics in Refractory and Relapsed Colorectal Cancer Trial</span> </caption> <col width="33%"/> <col width="24%"/> <col width="24%"/> <col width="18%"/> <tbody class="Headless"> <tr class="First"> <td class="Botrule Lrule Rrule Toprule" valign="top"></td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection +</span> <br/> <span class="Bold">FU/LV N = 152</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection</span> </p> <p> <span class="Bold"> N = 156</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">FU/LV N = 151</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Sex: Male (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">57.2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">60.9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">54.3</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">        Female (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">42.8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">39.1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">45.7</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Median age (years)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">59.0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">61.0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">60.0</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  Range</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">22–88</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">27–79</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">21–80</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="4" valign="top"> <p class="First">Race (%)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  Caucasian</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">88.8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">84.6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">87.4</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  Black</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5.9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7.1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">7.9</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  Asian</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2.6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2.6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1.3</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  Other</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2.6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">5.8</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3.3</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="4" valign="top"> <p class="First">KPS (%)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  70-100</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">95.4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">92.3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">94.7</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  50-60</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2.0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4.5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2.6</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  Not reported</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2.6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">3.2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2.6</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Prior radiotherapy (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">25.0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">19.2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">25.2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Prior pelvic radiation (%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">21.1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">13.5</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">18.5</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="4" valign="top"> <p class="First">Number of metastatic sites (%)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">25.7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">31.4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">27.2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  ≥2</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">74.3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">67.9</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">72.2</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" colspan="4" valign="top"> <p class="First">Liver involvement (%)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  Liver only</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">18.4</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">25.6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">22.5</p> </td> </tr> <tr class="Last"> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">  Liver + other</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">53.3</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">59.0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">60.3</p> </td> </tr> </tbody> </table></div>

The median number of cycles administered per patient was 6 for the oxaliplatin injection and fluorouracil/leucovorin combination and 3 each for fluorouracil/leucovorin alone and oxaliplatin injection alone. Patients treated with the combination of oxaliplatin injection and fluorouracil/leucovorin had an increased response rate compared to patients given fluorouracil/leucovorin or oxaliplatin alone. Efficacy results are summarized in Tables 24 and 25.

<div class="scrollingtable"><table width="97%"> <caption> <span>Table 24: Response Rates in Refractory and Relapsed Colorectal Cancer Clinical Trial - ITT Analysis</span> </caption> <col width="31%"/> <col width="19%"/> <col width="19%"/> <col width="32%"/> <tbody class="Headless"> <tr class="First"> <td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Best Response</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection + FU/LV N=152</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection N=156</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">FU/LV N=151</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Complete Response</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Partial Response</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">13 (9%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2 (1%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">P-value</p> </td><td align="center" class="Botrule Rrule" colspan="3" valign="top"> <p class="First">0.0002 FU/LV vs Oxaliplatin Injection + FU/LV</p> </td> </tr> <tr class="Last"> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">95% CI</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4.6%, 14.2%</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0.2%, 4.6%</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">0, 2.4%</p> </td> </tr> </tbody> </table></div>

<div class="scrollingtable"><table width="90%"> <caption> <span>Table 25: Radiographic Time to Progression (TTP)* in Refractory and Relapsed Colorectal Cancer Clinical Trial</span> </caption> <col width="45%"/> <col width="14%"/> <col width="18%"/> <col width="22%"/> <tbody class="Headless"> <tr class="First"> <td align="center" class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First"> <br/> <br/> <span class="Bold">Arm</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection + FU/LV N=152</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">Oxaliplatin Injection N=156</span> </p> </td><td align="center" class="Botrule Rrule Toprule" valign="top"> <p class="First"> <span class="Bold">FU/LV N=151</span> </p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Number of progressors</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">50</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">101</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">74</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Number of patients with no radiological evaluation beyond baseline</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">17 (11%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">16 (10%)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">22 (15%)</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">Median TTP (months)</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4.6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1.6</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">2.7</p> </td> </tr> <tr> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">95% CI</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">4.2, 6.1</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1.4, 2.7</p> </td><td align="center" class="Botrule Rrule" valign="top"> <p class="First">1.8, 3.0</p> </td> </tr> <tr class="Last"> <td class="Botrule" colspan="4" valign="top"> <p class="First"> <span class="Sup">*</span>This is not an ITT analysis. Events were limited to radiographic disease progression documented by independent review of radiographs. Clinical progression was not included in this analysis, and 18% of patients were excluded from the analysis based on unavailability of the radiographs for independent review. </p> </td> </tr> </tbody> </table></div>

At the time of the interim analysis 49% of the radiographic progression events had occurred. In this interim analysis an estimated 2-month increase in median time to radiographic progression was observed compared to fluorouracil/leucovorin alone.

{ "type": "", "children": [], "text": "" }

Oxaliplatin Injection USP is supplied in clear, glass, single-dose vials with gray elastomeric stoppers and aluminum flip-off seals containing 50 mg or 100 mg of oxaliplatin as a clear, colorless, sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL. 

{ "type": "p", "children": [], "text": "Oxaliplatin Injection USP is supplied in clear, glass, single-dose vials with gray elastomeric stoppers and aluminum flip-off seals containing 50 mg or 100 mg of oxaliplatin as a clear, colorless, sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL. " }

NDC 68001-468-36: 50 mg/10 mL single-dose vial with flip-off seal individually packaged in a carton.

{ "type": "p", "children": [], "text": "NDC 68001-468-36: 50 mg/10 mL single-dose vial with flip-off seal individually packaged in a carton." }

NDC 68001-468-37: 100 mg/20 mL single-dose vial with flip-off seal individually packaged in a carton.

{ "type": "p", "children": [], "text": "NDC 68001-468-37: 100 mg/20 mL single-dose vial with flip-off seal individually packaged in a carton." }

Store at 25°C (77°F); excursions permitted between 15 to 30°C (59 to 86°F). [See USP Controlled Room Temperature]. Do not freeze and protect from light (keep in original outer carton). Discard unused portion.

{ "type": "p", "children": [], "text": "Store at 25°C (77°F); excursions permitted between 15 to 30°C (59 to 86°F). [See USP Controlled Room Temperature]. Do not freeze and protect from light (keep in original outer carton). Discard unused portion." }

Oxaliplatin Injection USP is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 The use of gloves is recommended. If a solution of Oxaliplatin Injection USP contacts the skin, wash the skin immediately and thoroughly with soap and water. If Oxaliplatin Injection USP contacts the mucous membranes, flush thoroughly with water.

{ "type": "p", "children": [], "text": "Oxaliplatin Injection USP is a cytotoxic drug. Follow applicable special handling and disposal procedures.\n \n 1 The use of gloves is recommended. If a solution of Oxaliplatin Injection USP contacts the skin, wash the skin immediately and thoroughly with soap and water. If Oxaliplatin Injection USP contacts the mucous membranes, flush thoroughly with water.\n\n " }

Hypersensitivity Reactions

{ "type": "p", "children": [], "text": "\nHypersensitivity Reactions\n" }

Advise patients of the potential risk of hypersensitivity and that oxaliplatin injection is contraindicated in patients with a history of hypersensitivity reactions to oxaliplatin and other platinum-based drugs. Instruct patients to seek immediate medical attention for signs of severe hypersensitivity reaction such as chest tightness; shortness of breath; wheezing; dizziness or faintness; or swelling of the face, eyelids, or lips [see Warnings and Precautions ( 5.1)].

{ "type": "p", "children": [], "text": "Advise patients of the potential risk of hypersensitivity and that oxaliplatin injection is contraindicated in patients with a history of hypersensitivity reactions to oxaliplatin and other platinum-based drugs. Instruct patients to seek immediate medical attention for signs of severe hypersensitivity reaction such as chest tightness; shortness of breath; wheezing; dizziness or faintness; or swelling of the face, eyelids, or lips\n \n [see Warnings and Precautions (\n \n 5.1)].\n \n \n" }

Peripheral Sensory Neuropathy

{ "type": "p", "children": [], "text": "\nPeripheral Sensory Neuropathy\n" }

Advise patients of the risk of acute reversible or persistent-type neurosensory toxicity. Advise patients to avoid cold drinks, use of ice, and exposure of skin to cold temperature or cold objects [see Warnings and Precautions ( 5.2)] .

{ "type": "p", "children": [], "text": "Advise patients of the risk of acute reversible or persistent-type neurosensory toxicity. Advise patients to avoid cold drinks, use of ice, and exposure of skin to cold temperature or cold objects\n \n [see Warnings and Precautions (\n \n 5.2)]\n \n .\n\n " }

Myelosuppression

{ "type": "p", "children": [], "text": "\nMyelosuppression\n" }

Inform patients that oxaliplatin injection can cause low blood cell counts and the need for frequent monitoring of blood cell counts. Advise patients to contact their healthcare provider immediately for bleeding, fever, particularly if associated with persistent diarrhea, or symptoms of infection develop [see Warnings and Precautions ( 5.3)] .

{ "type": "p", "children": [], "text": "Inform patients that oxaliplatin injection can cause low blood cell counts and the need for frequent monitoring of blood cell counts. Advise patients to contact their healthcare provider immediately for bleeding, fever, particularly if associated with persistent diarrhea, or symptoms of infection develop\n \n [see Warnings and Precautions (\n \n 5.3)]\n \n .\n\n " }

Posterior Reversible Encephalopathy Syndrome

{ "type": "p", "children": [], "text": "\nPosterior Reversible Encephalopathy Syndrome\n" }

Advise patients of the potential effects of vision abnormalities, in particular transient vision loss (reversible following therapy discontinuation), which may affect the patients' ability to drive and use machines [see Warnings and Precautions ( 5.4)] .

{ "type": "p", "children": [], "text": "Advise patients of the potential effects of vision abnormalities, in particular transient vision loss (reversible following therapy discontinuation), which may affect the patients' ability to drive and use machines\n \n [see Warnings and Precautions (\n \n 5.4)]\n \n .\n\n " }

Pulmonary Toxicity

{ "type": "p", "children": [], "text": "\nPulmonary Toxicity\n" }

Advise patients to report immediately to their healthcare provider any persistent or recurrent respiratory symptoms, such as non-productive cough and dyspnea [see Warnings and Precautions ( 5.5)] .

{ "type": "p", "children": [], "text": "Advise patients to report immediately to their healthcare provider any persistent or recurrent respiratory symptoms, such as non-productive cough and dyspnea\n \n [see Warnings and Precautions (\n \n 5.5)]\n \n .\n\n " }

Hepatotoxicity

{ "type": "p", "children": [], "text": "\nHepatotoxicity\n" }

Advise patients to report signs or symptoms of hepatic toxicity to their healthcare provider [see Warnings and Precautions ( 5.6)].

{ "type": "p", "children": [], "text": "Advise patients to report signs or symptoms of hepatic toxicity to their healthcare provider\n \n [see Warnings and Precautions (\n \n 5.6)].\n \n \n" }

QT Interval Prolongation

{ "type": "p", "children": [], "text": "\nQT Interval Prolongation\n" }

Advise patients that oxaliplatin injection can cause QTc interval prolongation and to inform their physician if they have any symptoms, such as syncope [see Warnings and Precautions ( 5.7)] .

{ "type": "p", "children": [], "text": "Advise patients that oxaliplatin injection can cause QTc interval prolongation and to inform their physician if they have any symptoms, such as syncope\n \n [see Warnings and Precautions (\n \n 5.7)]\n \n .\n\n " }

Rhabdomyolysis

{ "type": "p", "children": [], "text": "\nRhabdomyolysis\n" }

Advise patients to contact their healthcare provider immediately for new or worsening signs or symptoms of muscle toxicity, dark urine, decreased urine output, or the inability to urinate [see Warnings and Precautions ( 5.8)].

{ "type": "p", "children": [], "text": "Advise patients to contact their healthcare provider immediately for new or worsening signs or symptoms of muscle toxicity, dark urine, decreased urine output, or the inability to urinate\n \n [see Warnings and Precautions (\n \n 5.8)].\n \n \n" }

Hemorrhage

{ "type": "p", "children": [], "text": "\nHemorrhage\n" }

Advise patients that oxaliplatin injection may increase the risk of bleeding and to promptly inform their healthcare provider of any bleeding episodes [see Warnings and Precautions ( 5.9)].

{ "type": "p", "children": [], "text": "Advise patients that oxaliplatin injection may increase the risk of bleeding and to promptly inform their healthcare provider of any bleeding episodes\n \n [see Warnings and Precautions (\n \n 5.9)].\n \n \n" }

Embryo-Fetal Toxicity

{ "type": "p", "children": [], "text": "\nEmbryo-Fetal Toxicity\n" }

Advise females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions ( 5.10), Use in Specific Populations ( 8.1)] .

{ "type": "p", "children": [], "text": "Advise females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy\n \n [see Warnings and Precautions (\n \n 5.10), Use in Specific Populations (\n \n 8.1)]\n \n .\n\n " }

Advise females of reproductive potential to use effective contraception during treatment with oxaliplatin injection and for 9 months after the final dose [see Use in Specific Populations ( 8.3)] .

{ "type": "p", "children": [], "text": "Advise females of reproductive potential to use effective contraception during treatment with oxaliplatin injection and for 9 months after the final dose\n \n [see Use in Specific Populations (\n \n 8.3)]\n \n .\n\n " }

Advise male patients with female partners of reproductive potential to use effective contraception during treatment with oxaliplatin injection and for 6 months after the final dose [see Use in Specific Populations ( 8.3), Nonclinical Toxicology ( 13.1)] .

{ "type": "p", "children": [], "text": "Advise male patients with female partners of reproductive potential to use effective contraception during treatment with oxaliplatin injection and for 6 months after the final dose\n \n [see Use in Specific Populations (\n \n 8.3), Nonclinical Toxicology (\n \n 13.1)]\n \n .\n\n " }

Lactation

{ "type": "p", "children": [], "text": "\nLactation\n" }

Advise women not to breastfeed during treatment with oxaliplatin injection and for 3 months after the final dose [see Use in Specific Populations ( 8.2)] .

{ "type": "p", "children": [], "text": "Advise women not to breastfeed during treatment with oxaliplatin injection and for 3 months after the final dose\n \n [see Use in Specific Populations (\n \n 8.2)]\n \n .\n\n " }

Infertility

{ "type": "p", "children": [], "text": "\nInfertility\n" }

Advise females and males of reproductive potential that oxaliplatin injection may impair fertility [see Use in Specific Populations ( 8.3), Nonclinical Toxicology ( 13.1)] .

{ "type": "p", "children": [], "text": "Advise females and males of reproductive potential that oxaliplatin injection may impair fertility\n \n [see Use in Specific Populations (\n \n 8.3), Nonclinical Toxicology (\n \n 13.1)]\n \n .\n\n " }

Gastrointestinal

{ "type": "p", "children": [], "text": "\nGastrointestinal\n" }

Advise patients to contact their healthcare provider for persistent vomiting, diarrhea, or signs of dehydration [see Adverse Reactions ( 6.1)] .

{ "type": "p", "children": [], "text": "Advise patients to contact their healthcare provider for persistent vomiting, diarrhea, or signs of dehydration\n \n [see Adverse Reactions (\n \n 6.1)]\n \n .\n\n " }

Drug Interactions

{ "type": "p", "children": [], "text": "\nDrug Interactions\n" }

Inform patients about the risk of drug interactions and the importance of providing a list of prescription and nonprescription drugs to their healthcare provider [see Drug Interactions ( 7)] .

{ "type": "p", "children": [], "text": "Inform patients about the risk of drug interactions and the importance of providing a list of prescription and nonprescription drugs to their healthcare provider\n \n [see Drug Interactions (\n \n 7)]\n \n .\n\n " }

Manufactured by: Qilu Pharmaceutical (Hainan) Co., Ltd.

{ "type": "p", "children": [], "text": "\nManufactured by:\n\n Qilu Pharmaceutical (Hainan) Co., Ltd.\n\n " }

Haikou, 570314, China

{ "type": "p", "children": [], "text": "Haikou, 570314, China" }

Revised: 08/2024

{ "type": "p", "children": [], "text": "Revised: 08/2024" }

For BluePoint Laboratories

{ "type": "p", "children": [], "text": "\nFor BluePoint Laboratories\n" }

Revised: 08/2024

{ "type": "p", "children": [], "text": "Revised: 08/2024" }

OXALIPLATIN (ox-Al-ah-platin) INJECTION USP,

{ "type": "p", "children": [], "text": "\nOXALIPLATIN (ox-Al-ah-platin) INJECTION USP,\n" }

for intravenous use

{ "type": "p", "children": [], "text": "\nfor intravenous use\n" }

What is the most important information I should know about Oxaliplatin Injection?

{ "type": "p", "children": [], "text": "\nWhat is the most important information I should know about Oxaliplatin Injection?\n" }

Oxaliplatin Injection can cause serious allergic reactions, including allergic reactions that can lead to death. Oxaliplatin Injection is a platinum-based medicine. Serious allergic reactions including death can happen in people who take oxaliplatin injection and who have had previous allergic reactions to platinum-based medicines. Serious allergic reactions can happen within a few minutes of your oxaliplatin injection infusion or any time during your treatment with oxaliplatin injection.

{ "type": "p", "children": [], "text": "\nOxaliplatin Injection can cause serious allergic reactions, including allergic reactions that can lead to death. Oxaliplatin Injection is a platinum-based medicine. Serious allergic reactions including death can happen in people who take oxaliplatin injection and who have had previous allergic reactions to platinum-based medicines. Serious allergic reactions can happen within a few minutes of your oxaliplatin injection infusion or any time during your treatment with oxaliplatin injection.\n " }

Get emergency help right away if you:

{ "type": "p", "children": [], "text": "\nGet emergency help right away if you:\n" }

{ "type": "ul", "children": [ "\nhave trouble breathing\n", "\nfeel like your throat is closing up\n", "\nchest tightness\n" ], "text": "" }

Call your doctor right away if you have any of the following signs or symptoms of an allergic reaction:

{ "type": "p", "children": [], "text": "Call your doctor right away if you have any of the following signs or symptoms of an allergic reaction:" }

{ "type": "ul", "children": [ "rash", "wheezing", "flushed face", "hives", "itching", "swelling of your lips or tongue, face or eyelids", "sudden cough", "dizziness or feel faint", "sweating", "chest pain" ], "text": "" }

See "What are the possible side effects of Oxaliplatin Injection?"for information about other serious side effects.

{ "type": "p", "children": [], "text": "See \n \"What are the possible side effects of Oxaliplatin Injection?\"for information about other serious side effects.\n " }

What is Oxaliplatin Injection?

{ "type": "p", "children": [], "text": "\nWhat is Oxaliplatin Injection?\n" }

Oxaliplatin Injection is an anti-cancer (chemotherapy) medicine that is used with other anti-cancer medicines called fluorouracil and leucovorin to treat people with:

{ "type": "p", "children": [], "text": "Oxaliplatin Injection is an anti-cancer (chemotherapy) medicine that is used with other anti-cancer medicines called fluorouracil and leucovorin to treat people with:" }

{ "type": "ul", "children": [ "stage III colon cancer after surgery to remove the tumor", "advanced colon or rectal cancer (colorectal cancer)" ], "text": "" }

It is not known if oxaliplatin injection is safe and effective in children.

{ "type": "p", "children": [], "text": "It is not known if oxaliplatin injection is safe and effective in children." }

Do not receive oxaliplatin injection ifyou are allergic to oxaliplatin or any of the ingredients in oxaliplatin injection or if you are allergic to other platinum-based medicines. See the end of this leaflet for a complete list of the ingredients in oxaliplatin injection.

{ "type": "p", "children": [], "text": "\nDo not receive oxaliplatin injection ifyou are allergic to oxaliplatin or any of the ingredients in oxaliplatin injection or if you are allergic to other platinum-based medicines. See the end of this leaflet for a complete list of the ingredients in oxaliplatin injection.\n " }

Ask your doctor if you are not sure if you have taken a platinum-based medicine.

{ "type": "p", "children": [], "text": "Ask your doctor if you are not sure if you have taken a platinum-based medicine." }

Before receiving oxaliplatin injection, tell your doctor about all of your medical conditions, including if you:

{ "type": "p", "children": [], "text": "\nBefore receiving oxaliplatin injection, tell your doctor about all of your medical conditions, including if you:\n" }

{ "type": "ul", "children": [ "have an infection", "have lung, liver, or kidney problems", "have bleeding problems", "have or had heart problems such as an abnormal heart test called an electrocardiogram (ECG or EKG), a condition called long QT syndrome, an irregular or slow heartbeat, or a family history of heart problems", "have had changes in the level of certain blood salt (electrolytes) levels, including potassium, magnesium, and calcium", "are pregnant or plan to become pregnant. Oxaliplatin Injection can harm your unborn baby. Tell your doctor right away if you become pregnant or think you may be pregnant during treatment with oxaliplatin injection.", "\nFemales who are able to become pregnant:\n", "o Your doctor will do a pregnancy test before you start treatment with oxaliplatin injection.", "o You should use effective birth control (contraception) during treatment with oxaliplatin injection and for 9 months after the final dose. Talk to your doctor about forms of birth control that may be right for you.\n\t\n \nMaleswith female partners who are able to become pregnant should use effective birth control during treatment with oxaliplatin injection and for 6 months after the final dose.\n \n", "are breastfeeding or plan to breastfeed. It is not known if oxaliplatin injection passes into your breast milk. Do not breastfeed during treatment with oxaliplatin injection and for 3 months after the final dose." ], "text": "" }

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

{ "type": "p", "children": [], "text": "Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements." }

Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.

{ "type": "p", "children": [], "text": "Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine." }

How will I receive Oxaliplatin Injection?

{ "type": "p", "children": [], "text": "\nHow will I receive Oxaliplatin Injection?\n" }

{ "type": "ul", "children": [ "Oxaliplatin Injection is given to you into your vein through an intravenous (IV) tube.", "Your doctor will prescribe oxaliplatin injection in a dose that is right for you.", "Your doctor may change how often you receive oxaliplatin injection, your dose, or how long your infusion will take.", "You and your doctor will decide how many oxaliplatin injection treatments you will receive.", "It is very important that you do exactly what your doctor and nurse tell you to do.", "Some medicines may be given to you before oxaliplatin injection to help prevent nausea and vomiting.", "Each treatment course is given to you over 2 days. You will receive oxaliplatin injection on the first day only.", "There are usually 14 days (2 weeks) between each chemotherapy treatment course.", "It is important for you to keep all of your medical appointments. Call your doctor if you miss an appointment. There may be special instructions for you." ], "text": "" }

Treatment Day 1:

{ "type": "p", "children": [], "text": "\nTreatment Day 1:\n" }

{ "type": "ul", "children": [ "Oxaliplatin Injection and leucovorin will be given through a thin plastic tube into a vein (intravenous infusion or IV) and given for 2 hours. You will be watched by a healthcare provider during this time.", "Right after the oxaliplatin injection and leucovorin are given, 2 doses of fluorouracil will be given. The first dose is given right away into your IV tube. The second dose will be given into your IV tube over the next 22 hours, using a pump device." ], "text": "" }

Treatment Day 2:

{ "type": "p", "children": [], "text": "\nTreatment Day 2:\n" }

You will notget oxaliplatin injection on Day 2. Leucovorin and fluorouracil will be given the same way as on Day 1.

{ "type": "p", "children": [], "text": "You \n will notget oxaliplatin injection on Day 2. Leucovorin and fluorouracil will be given the same way as on Day 1.\n " }

The fluorouracil will be given through your IV with a pump. If you have any problems with the pump or the tube, call your doctor, your nurse, or the person who is responsible for your pump. Do not let anyone other than a healthcare provider touch your infusion pump or tubing.

{ "type": "p", "children": [], "text": "The fluorouracil will be given through your IV with a pump. If you have any problems with the pump or the tube, call your doctor, your nurse, or the person who is responsible for your pump. Do not let anyone other than a healthcare provider touch your infusion pump or tubing." }

What should I avoid while receiving Oxaliplatin Injection?

{ "type": "p", "children": [], "text": "\nWhat should I avoid while receiving Oxaliplatin Injection?\n" }

{ "type": "ul", "children": [ "Avoid cold temperatures and cold objects. Cover your skin if you go outdoors in cold temperatures.", "Do not drink cold drinks or use ice cubes in drinks.", "Do not put ice or ice packs on your body.", "Oxaliplatin Injection can cause dizziness, vision problems, or vision loss that can affect your ability to drive or use machines. You should not drive or operate machinery if you develop these symptoms while receiving oxaliplatin injection." ], "text": "" }

See " How can I reduce the side effects caused by cold temperatures?" for more information.

{ "type": "p", "children": [], "text": "See \" \n How can I reduce the side effects caused by cold temperatures?\" for more information.\n " }

Talk with your doctor and nurse about your level of activity during treatment with oxaliplatin injection. Follow their instructions.

{ "type": "p", "children": [], "text": "Talk with your doctor and nurse about your level of activity during treatment with oxaliplatin injection. Follow their instructions." }

What are the possible side effects of Oxaliplatin Injection?

{ "type": "p", "children": [], "text": "\nWhat are the possible side effects of Oxaliplatin Injection?\n" }

Oxaliplatin Injection can cause serious side effects, including:

{ "type": "p", "children": [], "text": "\nOxaliplatin Injection can cause serious side effects, including:\n " }

{ "type": "ul", "children": [ "\nSee \"What is the most important information I should know about Oxaliplatin Injection?\"\n", "\nNerve problems.Oxaliplatin Injection can affect how your nerves work and make you feel. Nerve problems may happen with the first treatment or within two days after your treatment with oxaliplatin injection. Nerve problems may last a short time (acute) or may become persistent. Symptoms may improve after stopping treatment with oxaliplatin injection. Exposure to cold or cold objects may cause or worsen nerve problems. Tell your doctor right away if you get any signs of nerve problems, including:\n\t\n \nvery sensitive to cold temperatures and cold objects\ntrouble breathing, swallowing, or saying words, jaw tightness, odd feelings in your tongue, or chest pressure\npain, tingling, burning (pins and needles, numb feeling) in your hands, feet, or around your mouth or throat, which may cause problems walking, fall and fall-related injuries, or problems performing activities of daily living\n\n" ], "text": "" }

For information on ways to lessen or help with nerve problems, see the section " How can I reduce the side effects caused by cold temperatures?" below.

{ "type": "p", "children": [], "text": "For information on ways to lessen or help with nerve problems, see the section \" \n How can I reduce the side effects caused by cold temperatures?\" below.\n " }

{ "type": "ul", "children": [ "\nSevere low blood cell counts (myelosuppression).Oxaliplatin injection when used with fluorouracil and leucovorin can cause low blood cells counts. Low blood cell counts are common with oxaliplatin injection when used with fluorouracil and leucovorin and can lead to serious infection and death. Your doctor will do blood tests to check your blood cell counts before starting oxaliplatin injection and during treatment. Tell your doctor right away if you have a fever greater than 100.9°F (38.3°C) or a prolonged fever greater than 100.4°F (38°C) for more than one hour (febrile neutropenia). Call your doctor right away if you get any of the following signs of infection:\n " ], "text": "" }

<div class="scrollingtable"><table width="100%"> <colgroup> <col width="50%"/> <col width="50%"/> </colgroup> <tbody class="Headless"> <tr class="First"> <td class="Toprule" valign="top"> <p class="First">o chills or shivering</p> </td><td class="Toprule" valign="top"> <p class="First">o burning or pain on urination</p> </td> </tr> <tr> <td valign="top"> <p class="First">o pain on swallowing</p> </td><td valign="top"> <p class="First">o redness or swelling at intravenous site</p> </td> </tr> <tr> <td valign="top"> <p class="First">o sore throat</p> </td><td valign="top"> <p class="First">o persistent diarrhea</p> </td> </tr> <tr class="Last"> <td class="Botrule" valign="top"> <p class="First">o cough that brings up mucus</p> </td><td class="Botrule" valign="top"></td> </tr> </tbody> </table></div>

{ "type": "table", "children": [], "text": "<div class=\"scrollingtable\"><table width=\"100%\">\n<colgroup>\n<col width=\"50%\"/>\n<col width=\"50%\"/>\n</colgroup>\n<tbody class=\"Headless\">\n<tr class=\"First\">\n<td class=\"Toprule\" valign=\"top\">\n<p class=\"First\">o chills or shivering</p>\n</td><td class=\"Toprule\" valign=\"top\">\n<p class=\"First\">o burning or pain on urination</p>\n</td>\n</tr>\n<tr>\n<td valign=\"top\">\n<p class=\"First\">o pain on swallowing</p>\n</td><td valign=\"top\">\n<p class=\"First\">o redness or swelling at intravenous site</p>\n</td>\n</tr>\n<tr>\n<td valign=\"top\">\n<p class=\"First\">o sore throat</p>\n</td><td valign=\"top\">\n<p class=\"First\">o persistent diarrhea</p>\n</td>\n</tr>\n<tr class=\"Last\">\n<td class=\"Botrule\" valign=\"top\">\n<p class=\"First\">o cough that brings up mucus</p>\n</td><td class=\"Botrule\" valign=\"top\"></td>\n</tr>\n</tbody>\n</table></div>" }

{ "type": "ul", "children": [ "\nPosterior Reversible Encephalopathy Syndrome (PRES).PRES is a rare condition that affects the brain. Tell your doctor right away if you have any of the following signs and symptoms of PRES:\n\n\t\n \nheadache\nconfusion or a change in the way you think\nseizures\nvision problems, such as blurriness or vision loss.\n\n", "\nLung Problems.Oxaliplatin injection can cause lung problems that may lead to death. Tell your doctor right away if you get any of the following symptoms as these may be indicators of a serious lung disease:\n " ], "text": "" }

<div class="scrollingtable"><table width="100%"> <colgroup> <col width="50%"/> <col width="50%"/> </colgroup> <tbody class="Headless"> <tr class="First"> <td class="Botrule Lrule Rrule Toprule" valign="top"> <p class="First">o shortness of breath</p> </td><td class="Botrule Rrule Toprule" valign="top"> <p class="First">o cough</p> </td> </tr> <tr class="Last"> <td class="Botrule Lrule Rrule" valign="top"> <p class="First">o wheezing</p> </td><td class="Botrule Rrule" valign="top"></td> </tr> </tbody> </table></div>

{ "type": "table", "children": [], "text": "<div class=\"scrollingtable\"><table width=\"100%\">\n<colgroup>\n<col width=\"50%\"/>\n<col width=\"50%\"/>\n</colgroup>\n<tbody class=\"Headless\">\n<tr class=\"First\">\n<td class=\"Botrule Lrule Rrule Toprule\" valign=\"top\">\n<p class=\"First\">o shortness of breath</p>\n</td><td class=\"Botrule Rrule Toprule\" valign=\"top\">\n<p class=\"First\">o cough</p>\n</td>\n</tr>\n<tr class=\"Last\">\n<td class=\"Botrule Lrule Rrule\" valign=\"top\">\n<p class=\"First\">o wheezing</p>\n</td><td class=\"Botrule Rrule\" valign=\"top\"></td>\n</tr>\n</tbody>\n</table></div>" }

{ "type": "ul", "children": [ "\nLiver problems (hepatotoxicity).Your doctor will do blood tests to check your liver when you start receiving oxaliplatin injection, and before each treatment course as needed.\n ", "\nHeart problems.Oxaliplatin injection can cause heart problems that have led to death. Your doctor may do blood and heart tests during treatment with oxaliplatin injection if you have certain heart problems. If you faint (lose consciousness), or have an irregular heartbeat or chest pain during treatment with oxaliplatin injection, get medical help right away as this may be a sign of a serious heart condition.\n ", "\nMuscle problems.Oxaliplatin injection can cause muscle damage (rhabdomyolysis) which can lead to death. Tell your doctor right away if you have muscle pain and swelling, along with weakness, fever, red-brown urine, decreased amount of urine or trouble urinating.\n ", "\nBleeding problems (hemorrhage).Oxaliplatin injection when used with fluorouracil and leucovorin can cause bleeding problems (hemorrhage) that can lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs or symptoms of bleeding, including:\n " ], "text": "" }

<div class="scrollingtable"><table width="100%"> <colgroup> <col width="50%"/> <col width="50%"/> </colgroup> <tbody class="Headless"> <tr class="First"> <td class="Toprule" valign="top"> <p class="First">o blood in your stools or black stools (looks like tar)</p> </td><td class="Toprule" valign="top"> <p class="First">o increased bruising</p> </td> </tr> <tr> <td valign="top"> <p class="First">o pink or brown urine</p> </td><td valign="top"> <p class="First">o dizziness</p> <p>o weakness</p> </td> </tr> <tr> <td valign="top"> <p class="First">o unexpected bleeding, or bleeding that is severe or you cannot control</p> </td><td valign="top"> <p class="First">o confusion</p> <p>o changes in speech</p> </td> </tr> <tr> <td valign="top"> <p class="First">o vomit blood or vomit that looks like coffee grounds</p> </td><td valign="top"> <p class="First">o headache that lasts a long time</p> </td> </tr> <tr class="Last"> <td class="Botrule" valign="top"> <p class="First">o cough up blood or blood clots</p> </td><td class="Botrule" valign="top"></td> </tr> </tbody> </table></div>

{ "type": "table", "children": [], "text": "<div class=\"scrollingtable\"><table width=\"100%\">\n<colgroup>\n<col width=\"50%\"/>\n<col width=\"50%\"/>\n</colgroup>\n<tbody class=\"Headless\">\n<tr class=\"First\">\n<td class=\"Toprule\" valign=\"top\">\n<p class=\"First\">o blood in your stools or black stools (looks like tar)</p>\n</td><td class=\"Toprule\" valign=\"top\">\n<p class=\"First\">o increased bruising</p>\n</td>\n</tr>\n<tr>\n<td valign=\"top\">\n<p class=\"First\">o pink or brown urine</p>\n</td><td valign=\"top\">\n<p class=\"First\">o dizziness</p>\n<p>o weakness</p>\n</td>\n</tr>\n<tr>\n<td valign=\"top\">\n<p class=\"First\">o unexpected bleeding, or bleeding that is severe or you cannot control</p>\n</td><td valign=\"top\">\n<p class=\"First\">o confusion</p>\n<p>o changes in speech</p>\n</td>\n</tr>\n<tr>\n<td valign=\"top\">\n<p class=\"First\">o vomit blood or vomit that looks like coffee grounds</p>\n</td><td valign=\"top\">\n<p class=\"First\">o headache that lasts a long time</p>\n</td>\n</tr>\n<tr class=\"Last\">\n<td class=\"Botrule\" valign=\"top\">\n<p class=\"First\">o cough up blood or blood clots</p>\n</td><td class=\"Botrule\" valign=\"top\"></td>\n</tr>\n</tbody>\n</table></div>" }

The most common side effects of Oxaliplatin Injection include:

{ "type": "p", "children": [], "text": "\nThe most common side effects of Oxaliplatin Injection include:\n " }

{ "type": "ul", "children": [ "numbness, pain, tingling, and burning along the nerves", "low white blood cells (blood cells important for fighting infection)", "low platelet count (important for clotting and to control bleeding)", "low red blood cells (blood cells that carry oxygen to the tissues)", "nausea", "changes in liver function tests", "diarrhea", "vomiting", "tiredness", "mouth sores" ], "text": "" }

Oxaliplatin injection may cause fertility problems in males and females. Talk to your doctor if this is a concern for you.

{ "type": "p", "children": [], "text": "Oxaliplatin injection may cause fertility problems in males and females. Talk to your doctor if this is a concern for you." }

Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of oxaliplatin injection. For more information, ask your doctor or pharmacist.

{ "type": "p", "children": [], "text": "Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of oxaliplatin injection. For more information, ask your doctor or pharmacist." }

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

{ "type": "p", "children": [], "text": "Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088." }

How can I reduce the side effects caused by cold temperatures?

{ "type": "p", "children": [], "text": "\nHow can I reduce the side effects caused by cold temperatures?\n" }

{ "type": "ul", "children": [ "Cover yourself with a blanket while you are getting your oxaliplatin injection infusion.", "Do not breathe deeply when exposed to cold air.", "Wear warm clothing in cold weather at all times. Cover your mouth and nose with a scarf or a pull-down cap (ski cap) to warm the air that goes to your lungs.", "Wear gloves when taking things from the freezer or refrigerator.", "Drink fluids warm or at room temperature.", "Always drink through a straw.", "\nDo notuse ice chips if you have nausea or mouth sores. Ask your doctor about what you can use.\n ", "Be aware that most metals are cold to touch, especially in the winter. These include your car door and mailbox. Wear gloves to touch cold objects.", "Do not run the air-conditioning at high levels in the house or in the car in hot weather.", "If your body gets cold, warm-up the affected part. If your hands get cold, wash them with warm water.", "Always let your doctor know \n beforeyour next treatment how well you did since your last visit.\n " ], "text": "" }

Your doctor may have other useful tips for helping you with side effects.

{ "type": "p", "children": [], "text": "Your doctor may have other useful tips for helping you with side effects." }

General information about the safe and effective use of Oxaliplatin Injection.

{ "type": "p", "children": [], "text": "\nGeneral information about the safe and effective use of Oxaliplatin Injection.\n" }

Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet.

{ "type": "p", "children": [], "text": "Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet." }

You can ask your doctor or pharmacist for information about oxaliplatin injection that is written for health professionals.

{ "type": "p", "children": [], "text": "You can ask your doctor or pharmacist for information about oxaliplatin injection that is written for health professionals." }

What are the ingredients in Oxaliplatin Injection?

{ "type": "p", "children": [], "text": "\nWhat are the ingredients in Oxaliplatin Injection?\n" }

Active ingredient: oxaliplatin

{ "type": "p", "children": [], "text": "Active ingredient: oxaliplatin" }

Inactive ingredient: water for injection

{ "type": "p", "children": [], "text": "Inactive ingredient: water for injection" }

Manufactured by: Qilu Pharmaceutical (Hainan) Co., Ltd.

{ "type": "p", "children": [], "text": "\nManufactured by:\n\nQilu Pharmaceutical (Hainan) Co., Ltd.\n " }

Haikou, 570314, China

{ "type": "p", "children": [], "text": "Haikou, 570314, China" }

For BluePoint Laboratories

{ "type": "p", "children": [], "text": "\nFor BluePoint Laboratories\n" }

Revised: 08/2024

{ "type": "p", "children": [], "text": "Revised: 08/2024" }

PRINCIPAL DISPLAY PANEL - 50 mg/10 mL Vial Container

{ "type": "p", "children": [], "text": "PRINCIPAL DISPLAY PANEL - 50 mg/10 mL Vial Container" }

NDC 68001-468-36

{ "type": "p", "children": [], "text": "NDC 68001-468-36" }

Oxaliplatin Injection USP

{ "type": "p", "children": [], "text": "Oxaliplatin Injection USP" }

50 mg/10 mL (5 mg/mL)

{ "type": "p", "children": [], "text": "50 mg/10 mL (5 mg/mL)" }

FOR INTRAVENOUS USE ONLY

{ "type": "p", "children": [], "text": "FOR INTRAVENOUS USE ONLY" }

SINGLE USE VIAL ONLY

{ "type": "p", "children": [], "text": "SINGLE USE VIAL ONLY" }

Sterile Aqueous Solution - Preservative Free

{ "type": "p", "children": [], "text": "Sterile Aqueous Solution - Preservative Free" }

See package insert for further required dilution

{ "type": "p", "children": [], "text": "See package insert for further required dilution" }

DO NOT MIX OR ADD TO SODIUM CHLORIDE/ CHLORIDE-CONTAINING SOLUTIONS

{ "type": "p", "children": [], "text": "DO NOT MIX OR ADD TO SODIUM CHLORIDE/\n \nCHLORIDE-CONTAINING SOLUTIONS\n " }

Rx only

{ "type": "p", "children": [], "text": "Rx only" }

Rev: 02/2025

{ "type": "p", "children": [], "text": "Rev: 02/2025" }

PRINCIPAL DISPLAY PANEL - 50 mg/10 mL Carton Label

{ "type": "p", "children": [], "text": "PRINCIPAL DISPLAY PANEL - 50 mg/10 mL Carton Label" }

NDC 68001-468-36

{ "type": "p", "children": [], "text": "NDC 68001-468-36" }

Oxaliplatin Injection USP 50 mg/10 mL (5 mg/mL)

{ "type": "p", "children": [], "text": "Oxaliplatin Injection USP\n \n50 mg/10 mL (5 mg/mL)\n " }

FOR INTRAVENOUS USE ONLY

{ "type": "p", "children": [], "text": "FOR INTRAVENOUS USE ONLY" }

SINGLE USE VIAL ONLY

{ "type": "p", "children": [], "text": "SINGLE USE VIAL ONLY" }

Sterile Aqueous Solution - Preservative Free

{ "type": "p", "children": [], "text": "Sterile Aqueous Solution - Preservative Free" }

See package insert for further required dilution

{ "type": "p", "children": [], "text": "See package insert for further required dilution" }

DO NOT MIX OR ADD TO

{ "type": "p", "children": [], "text": "DO NOT MIX OR ADD TO" }

SODIUM CHLORIDE/CHLORIDE-CONTAINING SOLUTIONS

{ "type": "p", "children": [], "text": "SODIUM CHLORIDE/CHLORIDE-CONTAINING SOLUTIONS" }

Rx only

{ "type": "p", "children": [], "text": "Rx only" }

Rev: 02/2025

{ "type": "p", "children": [], "text": "Rev: 02/2025" }

PRINCIPAL DISPLAY PANEL - 100 mg/20 mL Vial Container

{ "type": "p", "children": [], "text": "PRINCIPAL DISPLAY PANEL - 100 mg/20 mL Vial Container" }

NDC 68001-468-37

{ "type": "p", "children": [], "text": "NDC 68001-468-37" }

Oxaliplatin Injection USP 100 mg/20 mL (5 mg/mL)

{ "type": "p", "children": [], "text": "Oxaliplatin Injection USP\n \n100 mg/20 mL (5 mg/mL)\n " }

FOR INTRAVENOUS USE ONLY SINGLE USE VIAL ONLY

{ "type": "p", "children": [], "text": "FOR INTRAVENOUS USE ONLY\n \nSINGLE USE VIAL ONLY\n " }

Sterile Aqueous Solution - Preservative Free

{ "type": "p", "children": [], "text": "Sterile Aqueous Solution - Preservative Free" }

See package insert for further required dilution

{ "type": "p", "children": [], "text": "See package insert for further required dilution" }

DO NOT MIX OR ADD TO SODIUM CHLORIDE/CHLORIDE-CONTAINING SOLUTIONS

{ "type": "p", "children": [], "text": "DO NOT MIX OR ADD TO\n \nSODIUM CHLORIDE/CHLORIDE-CONTAINING SOLUTIONS\n " }

Rx only

{ "type": "p", "children": [], "text": "Rx only" }

Rev: 02/2025

{ "type": "p", "children": [], "text": "Rev: 02/2025" }

PRINCIPAL DISPLAY PANEL - 100 mg/20 mL Carton

{ "type": "p", "children": [], "text": "PRINCIPAL DISPLAY PANEL - 100 mg/20 mL Carton" }

NDC 68001-468-37

{ "type": "p", "children": [], "text": "NDC 68001-468-37" }

Oxaliplatin Injection USP 100 mg/20 mL (5 mg/mL)

{ "type": "p", "children": [], "text": "Oxaliplatin Injection USP\n \n\n100 mg/20 mL (5 mg/mL)\n " }

FOR INTRAVENOUS USE ONLY SINGLE USE VIAL ONLY

{ "type": "p", "children": [], "text": "FOR INTRAVENOUS USE ONLY\n \nSINGLE USE VIAL ONLY\n " }

Sterile Aqueous Solution - Preservative Free

{ "type": "p", "children": [], "text": "Sterile Aqueous Solution - Preservative Free" }

See package insert for further required dilution

{ "type": "p", "children": [], "text": "See package insert for further required dilution" }

DO NOT MIX OR ADD TO SODIUM CHLORIDE/ CHLORIDE-CONTAINING SOLUTIONS

{ "type": "p", "children": [], "text": "DO NOT MIX OR ADD TO\n \nSODIUM CHLORIDE/\n \nCHLORIDE-CONTAINING SOLUTIONS\n " }

Rx only

{ "type": "p", "children": [], "text": "Rx only" }

Rev: 02/2025

{ "type": "p", "children": [], "text": "Rev: 02/2025" }